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3ABSTRACT
Diseases of the posterior segment of the eye, such as age-related macular
degeneration and diabetic retinopathy, are the leading causes of blindness in
the developed world. Drug delivery to the posterior eye tissues, including the
retina and choroid, is accomplished by frequent intravitreal injections, which
are expensive and burdensome to the health care providers and patients, and
may cause harmful side effects. Therefore, sustained and less invasive delivery
strategies are vitally needed to improve the treatment. Melanin pigment is
found at high concentrations in ocular tissues, and many clinical drugs bind to
it.  Targeting  the  pigment  to  obtain  sustained  drug  action  in  ocular  tissues
could be a feasible approach for improving ocular drug therapy. Therefore, this
thesis  project  aimed  to  study  the  effects  of  pigment  binding  on
pharmacokinetics in the eye with in vitro, in vivo and in silico methods. In
addition,  we  investigated  drug  binding  to  the  vitreous  humor,  as  it  may
participate in modulating ocular pharmacokinetics and has been studied only
scarcely.
Melanin is a negatively charged, hydrophobic polymer, and it is expected
to  bind  all  basic  and  lipophilic  drugs  to  some  extent.  Melanin  is  located  in
intracellular melanosomes, which are cell organelles surrounded by a lipid
membrane,  and are expected to have an acidic  intraluminal  pH. Due to the
location of melanin, cellular and physiological factors act in concert with the
binding  to  the  melanin  polymer,  to  impact  ocular  pharmacokinetics  of
melanin-binding drugs. We investigated pigment binding and related cellular
and  physiological  factors  with  seven  small  molecule  drug  or  drug-like
compounds: chloroquine, timolol, nadolol, propranolol, methotrexate, 5(6)-
carboxy-2?,7?-dichlorofluorescein (CDCF) and diclofenac. A pH-dependent
binding  (pH  5.0  vs.  7.4)  to  isolated  porcine  ocular  melanin  was  observed,
mainly with the acidic compounds that are less negatively charged and bind
better  at  pH  5.0.  Therefore,  pH  plays  an  important  role  in  drug-melanin
binding in the case of acidic drugs, but is less important in the case of basic
drugs. The binding parameters, maximum binding capacity and affinity, were
reliably  calculated  with  the  Sips  binding  isotherm instead  of  the  commonly
used Langmuir isotherms. The Sips isotherm is in line with the heterogeneous
nature of the melanin surface to where the drugs bind, and, therefore, is better
suitable for parameter analysis. Cellular uptake and intracellular binding in
pigmented retinal pigment epithelial cells were shown to correlate with
melanin binding, but other factors, such as lipophilicity of the drug, also need
to  be  taken  into  account.  Pharmacokinetic  simulations  of  the  retention  of
drugs in pigmented posterior segment tissues demonstrated that low drug
permeability in the plasma and melanosomal membranes and the entrapment
of  positively  charged  drugs  in  the  melanosome  increases  melanin  binding
related retention in these tissues. In addition, both the intracellular binding
4experiments with pigmented cells and the pharmacokinetic simulations
showed that only a small fraction (~0.01%) of the highest binding drug of this
study, chloroquine, is in the free form inside the cells. The free form of the drug
elicits the drug action (beneficial or harmful), and it is, therefore, important to
differentiate between the free and total drug inside the cells when assessing
drug response. Furthermore, we demonstrated the distribution and retention
of 123I-chloroquine  in  the  eyes  of  pigmented  but  not  albino  rats  after
intravenous  administration,  establishing  the  use  of  single  photon  emission
computed tomography/computed tomography imaging in monitoring
melanin binding related kinetics in vivo. All in all, in the variety of experiments
performed,  melanin  binding  was  shown  to  have  a  major  impact  on  ocular
pharmacokinetics in pigmented tissues. In addition to investigating melanin
binding, drug binding to the vitreous humor was studied with a cassette of 35
clinical small molecule drugs. The binding was rather low and vitreal binding
was concluded to have only a modest effect on ocular pharmacokinetics.
In conclusion, this thesis project generated important information of the
extensive pharmacokinetic impact of drug-melanin binding in ocular tissues.
In addition, we demonstrated the moderate pharmacokinetic impact of vitreal
drug binding, which is not comparable to melanin binding. The computational
models developed on melanin binding and its pharmacokinetic implications
can be used in drug discovery and development. The in vitro methods can also
be implemented to the industry scale drug development process. The results
obtained support the feasibility of using melanin targeting to attain sustained
action  in  pigmented  ocular  tissues,  but  more  research  into  the  approach  is
needed before it can be employed in practice.
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1 INTRODUCTION
Eyesight has always been considered the most important of our five senses.
The fear of sight loss in people diagnosed with conditions with a prognosis of
blindness can lead to severe psychological distress (De Leo et al., 1999). Visual
impairment has been shown to decrease the quality of  life  more than many
other chronic conditions (e.g. cancer, ischemic heart disease, diabetes, and
depression) (Park et al.,  2015) and the quality of life is lower in people with
acquired than with congenital blindness (Vuleti? et al., 2016). Diseases of the
posterior  segment  of  the  eye,  such  as  diabetic  retinopathy  (DR)  and  age-
related macular degeneration (AMD), are the leading cause of irreversible
blindness  in  developed  countries  (Wong  et  al.,  2014).  These  diseases  are
mostly a  problem of  the aging population,  as for example the prevalence of
age-related  maculopathy  in  the  Finnish  population  increased  from  1%  in
people aged 20-64 to 27% in the population aged 85 and over (Laitinen et al.,
2009). Also other vision-threatening diseases of the eye, such as glaucoma and
cataract,  increase with age.  Thus,  the exponential  aging of  the population is
likely to increase the prevalence of ocular diseases remarkably. Globally, there
are expected to be 200 million AMD patients in 2020 and 290 million in 2040
(Wong et al., 2014).
There are great challenges in treating diseases of the posterior eye segment;
some of the diseases do not have effective drug treatments, and drug delivery
to  reach  the  target  tissues  poses  a  challenge  for  the  treatment  and  drug
development. Currently, AMD is treated with anti-angiogenic agents
administered through intravitreal injections given every 4-6 weeks (Tuuminen
et al., 2017). In the United States alone, 4 million intravitreal injections were
given in 2013, and the yearly number was expected to rise to 6-8 million by
2016 (Williams, 2014). This invasive treatment may be unpleasant, distressing
and  frightening  for  the  patient,  can  cause  harmful  side  effects,  such  as
intraocular inflammation and ocular hemorrhage, requires a specialized
expert to administer the drug, and is very expensive. To improve the treatment
of ocular diseases, long-acting delivery strategies are needed, especially in the
case  of  small  molecule  drugs  (e.g.  corticosteroids  and  antibiotics)  that  are
cleared rapidly from the vitreous. In the case of the posterior eye segment,
which  is  difficult  to  reach  through  topical  delivery  to  the  ocular  surface,
sustained  delivery  of  the  drug  would  decrease  the  frequency  of  invasive
intravitreal administration. Targeting the posterior tissues could enable the
use of less invasive administration routes, such as topical or oral delivery.
Many  clinical  drugs  bind  to  melanin  pigment  which  is  found  at  high
concentrations in ocular tissues. This thesis aimed to study the possibility of
using pigment binding of drugs as an ocular targeting strategy by investigating
how the binding affects the pharmacokinetics in the eye. Pigment binding is a
well-known  phenomenon  but  systematic  research  of  the  properties  of  the
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drugs  that  bind  and  other  cellular  and  physiological  factors  affecting  the
binding is missing. Additionally, drug binding to the vitreous humor and its
impact on vitreal pharmacokinetics has been studied only scarcely. Therefore,
in addition to melanin binding, we investigated drug binding to the vitreous
humor. This study increases the understanding of pigment binding and vitreal
binding in ocular drug treatment and provides tools  for  the development of
new drugs.
Review of the literature
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2 REVIEW OF THE LITERATURE
2.1 PHARMACOKINETICS IN THE EYE
The eye is a well-protected organ with a variety of tissue and dynamic barriers
surrounding it (Hornof et al., 2005; Urtti, 2006). In drug delivery, these
barriers need to be penetrated in order to elicit the effect in the targeted tissue.
Anterior  tissues  of  the  eye,  the  cornea,  conjunctiva,  aqueous  humor,  iris,
ciliary  body,  and  trabecular  meshwork,  are  mainly  treated  by  topical  drug
administration on the surface of the eye. This is accomplished by eye drops,
ointments or gels. The posterior segment tissues, the retina, choroid, sclera
and vitreous, are more difficult to reach by topical delivery, and local invasive
drug delivery, such as intravitreal injection, is necessary. To develop effective
drugs  and  drug  delivery  strategies  for  ocular  diseases,  a  profound
understanding of the ocular barriers is required.
2.1.1 BARRIERS IN OCULAR DRUG DELIVERY
Cornea and precorneal loss
Drug targets for ocular diseases are generally located in the inner parts of the
eye and the drug has to penetrate at least the outermost tissue of the eye, the
cornea. After the instillation of an eye drop, less than 5% of the drug generally
passes the cornea to reach the aqueous humor (Maurice and Mishima, 1984).
The majority of the drug is lost by the so called precorneal loss, either through
overflow or nasolacrimal drainage of the tear fluid or through absorption via
the conjunctiva to the systemic circulation.
In addition to the precorneal loss, the cornea itself poses a barrier for drug
penetration (Figure 1, [1]). It is composed of five layers; epithelium, Bowman’s
layer, stroma, Descemet’s membrane, and endothelium (Remington, 2012).
The epithelium is five to seven cell layers thick (~50 μm), and tight junctions
join  the  cells  of  the  surface  layer.  Drugs  penetrate  the  epithelium  mainly
transcellularly, benefiting the permeation of lipophilic compounds. The
stroma of the cornea is hydrophilic (thickness ~500 μm), and thus favors the
penetration of hydrophilic compounds. The endothelium is a single cell layer
with relatively leaky tight junctional complexes and its contribution to the
barrier functions of the cornea is minor. Both Bowman’s layer and Descemet’s
membrane  are  collagenous  layers,  each  5-15  μm  thick,  but  neither  of  these
layers is relevant for the barrier properties of the cornea (Durairaj, 2016). In
total, lipophilicity improves the drug permeation across the cornea, whereas
hydrogen  bonding  capacity,  interpreted  as  lowering  the  permeability  in  the
hydrophilic, collagen-rich stroma, decreases the permeation (Kidron et al.,
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2010). The permeability values for corneal permeability vary roughly from
5 × 10-7 cm/s for the most hydrophilic compounds towards 5 × 10-5 cm/s for
the more lipophilic compounds (Kidron et al.,  2010; Prausnitz and Noonan,
1998).
Figure 1 Structure of the eye and barriers in ocular drug delivery. The absorption and
elimination of the drug takes place as follows: [1] Absorption through the cornea, [2]
absorption through the non-corneal route through the conjunctiva and sclera, [3]
distribution from the systemic circulation to the anterior chamber, [4] elimination
through aqueous humor outflow through the Schlemm’s canal and trabecular
meshwork, [5] elimination through the circulation of the iris, [6] distribution from the
systemic circulation to the vitreous through the blood-retina barrier, [7] intravitreal
delivery, [8] elimination through the blood-retina barrier, and [9] elimination through
the anterior route to the posterior and anterior chambers. Figure from Hornof et al.
(2005), reprinted with permission from Elsevier.
Conjunctiva
After topical delivery, the drug can also enter the eye through the non-corneal
route  via  the  conjunctiva  and  sclera  (Figure  1,  [2]).  The  conjunctiva  is  a
vascularized tissue with an apical epithelial layer and inner stroma
(Remington, 2012). It can be divided into palpebral conjunctiva covering the
inner  surface  of  the  eyelids  and  to  bulbar  conjunctiva  covering  the  visible
scleral  surface  in  the  anterior  section  of  the  eye.  The  forniceal  conjunctiva
connects these two parts. The epithelium contains tight junctions, which are,
however, leakier than the corresponding junctions in the corneal epithelium
(Ahmed  and  Patton,  1985).  In  rabbit,  the  pore  size  of  the  conjunctival
Review of the literature
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epithelium was shown to be twice that of the corneal epithelium, and the pore
density  15  times  higher  (Hämäläinen  et  al.,  1997).  The  conjunctival  stroma
contains the blood and lymphatic flow that can clear the drug to the systemic
blood circulation. When penetrating the bulbar conjunctiva, the drug that is
not  cleared  by  the  blood  circulation,  reaches  the  scleral  tissue.  This  non-
corneal route is useful mainly for compounds that penetrate the cornea poorly,
e.g. very hydrophilic molecules and macromolecules (Ahmed and Patton,
1985; Järvinen et al., 1995). The posterior segment of the eye is also possible
to reach through this route, as the drug, after penetrating the sclera, can gain
access  to  the  choroidal  and  retinal  tissues.  Permeability  in  the  conjunctiva
varies around 1 × 10-6 – 5 × 10-5 cm/s (Prausnitz and Noonan, 1998; Ramsay
et al.,  2017),  and has been shown to depend on molecular features,  such as
polar  surface  area  and  hydrogen  bond  donor  count  (Ramsay  et  al.,  2017).
Conjunctival  permeability  does  not,  however,  directly  correlate  with  the
lipophilicity (logD) of the compound (Prausnitz and Noonan, 1998; Ramsay et
al., 2017).
Sclera
The  sclera  consists  of  the  episclera  and  scleral  stroma.  In  addition,  the
suprachoroid lamina (lamina fusca), residing inner to the scleral stroma, can
either be counted as a part  of  the sclera  or part  of  the choroid.  In reality,  it
consists  of  parts  of  both tissues (Remington,  2012),  and forms a loose layer
that does not play a role in the barrier functions of the sclera. It can, however,
be used as a delivery space for suprachoroidal injections. The episclera is also
a loose tissue, but on the outer surface of the sclera. It is vascularized and can
participate in clearing drugs to the systemic circulation,  but otherwise does
not play a role in the barrier properties of the sclera (Chan et al., 2010; Ranta
and Urtti, 2006). The scleral stroma is considered to be an avascular tissue;
even though some vessels traverse the tissue, it has no capillary system
(Remington, 2012). It is formed mainly of collagen fibrils and proteoglycans.
The barrier properties and the structure of the sclera are similar to those of the
corneal stroma (Prausnitz and Noonan, 1998). Scleral permeability is mainly
determined by the molecular size, macromolecules permeating slower than
small  molecules.  Compared  to  the  whole  cornea,  the  sclera  is  a  more
permeable tissue (Papp for  small  molecules 5 ×  10-6 -  5  ×  10-5 cm/s) and the
more hydrophilic the drug, the larger seems to be the difference in corneal and
scleral permeability (Prausnitz and Noonan, 1998).
Choroid
The  choroid  is  a  densely  vascularized,  loose  connective  tissue.  Its  barrier
properties in drug permeation are mainly due to its blood flow (Robinson et
al.,  2006).  It  has  been  shown,  however,  that  permeation  through  the  non-
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corneal  route  is  not  greatly  affected  by  the  choroidal  blood  flow  but
conjunctival and episcleral blood flow play a more important role (Chan et al.,
2010;  Robinson  et  al.,  2006).  Contrasting  reports  claim  that  the  choroidal
blood  flow  does  play  a  role  (Ranta  et  al.,  2010;  Ranta  and  Urtti,  2006),
therefore, more results are needed to assess the relevance of its barrier
function in ocular drug distribution, especially in human. The choroid is
densely pigmented (Menon et al., 1992), influencing the pharmacokinetics of
drugs that bind to melanin pigment. Melanin binding does not contribute to
the barrier properties of the tissue as such, but melanin can form a depot of
the drug and lower the free concentration in the tissue. It can also prolong the
lag time in drug permeation (Pitkänen et al., 2005).
Retinal pigment epithelium
The retinal pigment epithelium (RPE), the outermost layer of the retina, is a
densely pigmented cell monolayer with tight junctions (Remington, 2012). It
is  a  part  of  the blood-retina barrier  and has a crucial  role in preventing the
penetration of xenobiotics to the retina. Permeability in the RPE depends on
the lipophilicity of the molecule, more lipophilic molecules permeating faster
(Pitkänen et al., 2005). Permeability of small molecules varies approximately
from 1 × 10-6  to 1 × 10-5 cm/s, but larger molecules can have permeabilities as
low as 3 × 10-8 cm/s (FITC-dextran 80 kDa) (Pitkänen et al., 2005). Compared
to the choroid, the RPE is a much greater barrier to drug permeation (Pitkänen
et al., 2005; Ranta et al., 2010). Permeabilities of FITC-dextrans were 10-100
fold  higher  in  the  excised  choroid  than  in  the  excised  RPE-choroid
(unpublished results, presented in Pitkänen et al. 2005). However, the blood
flow  of  the  choroid,  missing  in  the  excised  tissues,  increases  the  barrier
function of the choroid. The melanin pigment in the RPE can cause a similar
depot effect for binding drugs as mentioned for choroidal pigment, but again,
does not participate in the barrier properties.
Vitreous
The vitreous humor, holding a volume of 4 ml in the human eye, is a gel-like
material constituting mainly of water (98-99.7%) (Le Goff and Bishop, 2008).
In addition, it contains structural collagens, mainly collagen type II,
responsible  for  the  gel  structure  and  tensile  strength  (Le  Goff  and  Bishop,
2008), and glycosaminoglycans, mainly hyaluronic acid, responsible for
stabilizing  the  collagen  network  (Bu  et  al.,  2015).  The  mesh  size  of  bovine
vitreous has been determined to be around 500 nm (Peeters et al., 2005; Xu
et al., 2013) and the vitreous does not pose a barrier for the diffusion of small
molecules or even larger macromolecules (therapeutic proteins have
diameters less than 10 nm). It can, however, hinder the diffusion of particles
larger than 500 nm, such as larger nanoparticles or microparticles for drug
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delivery. The vitreous affects the movement of positively charged particles
(>500  nm)  as  the  vitreous  bears  a  net  negative  charge  due  to  the  anionic
moieties (carboxylic  and sulphate groups) of  the glycosaminoglycans (Xu et
al.,  2013).  The  aging  vitreous  tends  to  liquefy,  the  total  fraction  of  gel
decreasing  from  80  to  ~50%  (Bishop,  2000;  Sebag,  1987),  but  this  is  not
expected to significantly modify the barrier properties.
Inner limiting membrane
The inner limiting membrane (ILM), an extrcellular matrix constituted mainly
of collagen, laminin and proteoglycans, resides between the retina and
vitreous  (Halfter  et  al.,  2008;  Peynshaert  et  al.,  2017).  It  is  the  basement
membrane  of  Müller  cells  in  the  retina.  It  is  approximately  3-4  μm  thick,
except  in  the  foveal  area,  where  it  is  considerably  thinner  (min.  20  nm)
(Henrich  et  al.,  2012).  The  ILM  can  be  a  barrier  for  retinal  penetration  of
proteins and nanoparticles (Hutton-Smith et al., 2017; Pitkänen et al., 2004),
and the permeation has been shown to depend more on the charge than the
size of the permeant (Pitkänen et al., 2004), with positive charge hindering the
permeation. For small molecules, the ILM has not been shown to be a barrier.
Blood-ocular barriers
The eye is protected by blood-ocular barriers both in the anterior and posterior
segments. The anterior blood-ocular barrier, the blood-aqueous barrier, is
composed of the endothelium of the iridial vessels and the non-pigmented
epithelium  of  the  ciliary  body  (Cunha-Vaz,  1979;  Cunha-Vaz  et  al.,  2011).
These cells have tight junctions that control the entrance of compounds from
the blood circulation to the aqueous humor (Figure 1, [3]). The blood-aqueous
barrier prevents plasma albumin from entering the aqueous, but small
amounts  of  plasma proteins  are  present  in  the  aqueous  humor  due  to  their
passage through the ciliary process capillaries (Schlingemann et al., 1998).
The posterior blood-ocular barrier, the blood-retina barrier, is composed
of the RPE and the endothelial cells of the retinal capillaries (Cunha-Vaz et al.,
2011). Both cell layers contain tight junctions, efficiently regulating the
permeability of ions, water, nutrients, and proteins to the retina. The choroidal
capillaries are relatively leaky, allowing passive diffusion of molecules up to 6-
12 nm in size (Sarin, 2010). Small molecule drugs and small macromolecules
can, therefore, gain access to the choroid, but further penetration through the
RPE to  the  neural  retina  is  limited.  The  RPE is,  nevertheless,  permeable  to
small molecules, especially to lipophilic compounds that can permeate the cell
membrane passively (Pitkänen et  al.,  2005),  and drug treatment with small
molecules  through  systemic  circulation  is  possible  (Figure  1,  [6]).  Drug
transporters  in  the  RPE  can  also  affect  the  permeation  of  this  barrier,  and
consequently affect the distribution of drugs from the systemic circulation to
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the retina and vitreous, and vice versa. Although multiple drug transporters,
such  as  multidrug  resistance  associated  protein  1  (MRP1),  -4,  and  -5,  have
been  identified  in  the  RPE  (Pelkonen  et  al.,  2017a),  their  impact  on
pharmacokinetics is complex and still not fully understood (Vellonen et al.,
2017).
2.1.2 DRUG DISTRIBUTION IN THE EYE
The different ocular barriers presented above affect the distribution of drugs
in  the  eye  depending  on  the  properties  of  the  drug  and  the  route  of  drug
delivery. Drug distribution between the different ocular tissues is presented in
Figure 2.
Figure 2 Drug distribution in the eye after topical, systemic and intravitreal delivery. The drug
can move between tissues (compartments) that share an edge. The common
permeation routes are displayed as arrows (dashed arrow indicates slower
permeation). AH, aqueous humor.
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Distribution in the anterior segment
Topical drug delivery on the surface of the eye results in effective therapeutic
concentrations of drugs only in the anterior tissues; the cornea, conjunctiva,
aqueous  humor,  iris  and  ciliary  body.  Drug  bioavailability  from  the  ocular
surface to the aqueous humor, due to precorneal loss and the corneal barrier
function,  is  generally  less  than  5%  (Maurice  and  Mishima,  1984).  After
entering the aqueous humor, the drug is distributed to the inner anterior
segment tissues,  such as the iris  and ciliary body (Figure 2).  The volume of
distribution (Vd)  of  drugs  in  the  aqueous  humor,  measured  after  an
intracameral  injection,  varies  from 2-  to  10-fold  the  volume of  the  aqueous
humor (Durairaj, 2016). Drug exposure to the tissues (cornea, iris, ciliary
body) is not necessarily the same as that of the aqueous humor, and the ratio
of tissue to aqueous humor exposure has been shown to vary from 1 to at least
800 (Durairaj, 2016). Increased tissue binding, caused by the lipophilicity of
the drug or by melanin binding, can increase the levels of drug in the tissues.
Clearance from the aqueous humor is mediated by the blood flow in the iris
and  the  outflow  of  the  aqueous  humor  (Figure  1,  [4],  [5])  (Maurice  and
Mishima, 1984). Hydrophilic compounds are eliminated by the turnover of the
aqueous humor (rate of ~3 μl/min, total aqueous volume ~250 μl) (Figure 2).
In  addition  to  the  outflow,  lipophilic  compounds  are  also  cleared  from  the
aqueous humor to the surrounding tissues (clearances up to 20-30 μl/min)
(Urtti, 2006). The half-lives of drugs in the aqueous humor are relatively short,
ranging from 0.4 to 2.2 h in rabbits (Durairaj, 2016).
The  drugs  that  permeate  the  cornea  poorly  (hydrophilic  molecules  and
macromolecules), enter the eye through the non-corneal route via the
conjunctiva and sclera (Figure 2). After the sclera, the drug faces the choroidal
blood flow. Clearance in the choroidal blood flow is dependent on size, small
molecules being cleared faster than macromolecules (Kim et al., 2008). It has
been shown that the distribution of the drug to the posterior segment tissues
after subconjunctival administration is greatly increased by halting the blood
circulation by euthanizing the animal or using an ex vivo eye (Kim et al., 2004,
2008; Robinson et al.,  2006). Thus, reaching therapeutic concentrations for
small  molecules  in  the  retina  is  difficult  through  the  sclera,  but  for  larger
molecules, such as therapeutic proteins that are cleared by the dynamic flows
more slowly, it is an achievable option (Kim et al., 2008; Ranta et al., 2010).
Ocular drug distribution after systemic delivery
The majority of  ocular blood flow is  in the choroid (Sebag et  al.,  1994).  The
choroidal  vessels  are  leaky  and  small  molecule  drugs  can  easily  enter  the
extravascular choroid from the blood flow (Figure 2). Further distribution to
the retina, however, is hindered by the RPE (outer blood-retina barrier)
(Figure 2).  The main factors affecting ocular distribution are unbound drug
fraction  in  the  plasma and  the  distribution  clearance  from the  blood  to  the
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vitreous (Vellonen et al., 2016). The unbound fraction alone does not predict
the distribution.  The lipophilicity  of  the drug does not correlate with ocular
distribution (Vellonen et al., 2016), even though the permeability in the RPE
has  been  shown  to  depend  on  lipophilicity  (Pitkänen  et  al.,  2005).  The
distribution clearance, however, depends on the lipophilicity, together with
the hydrogen bonding of the drug, therefore, lipophilicity does play a role in
ocular distribution after systemic administration.
The  drug  can  also  access  the  tissues  of  the  anterior  segment  of  the  eye
through the blood-aqueous barrier. Some ocular diseases, such as glaucoma,
can be treated with systemic delivery, but the drawback of this approach is the
high systemic concentrations needed to effectively deliver the drug to the eye.
Intravitreal distribution
Treating  the  diseases  of  the  posterior  segment  is  generally  accomplished  as
intravitreal  injections  because  this  can  provide  drug  access  to  the  retina.
Vitreous does not pose a barrier for the diffusion of small molecules or even
macromolecules and drugs diffuse within the vitreous after injection (del Amo
et al., 2017). Vitreal clearance of drugs depends on their capability to pass the
blood-ocular barriers; small molecules are cleared mainly via the so called
posterior elimination pathways (the blood-ocular barriers) (Figure 1, [8]), and
macromolecules, which do not penetrate these barriers easily, are cleared
through  the  anterior  route,  by  the  aqueous  humor  outflow  (Figure  1,  [9],
Figure  2)  (Maurice  and  Mishima,  1984;  Urtti,  2006).  Lipophilic  small
molecules, which pass the blood-ocular barriers easily, have the shortest half-
lives in the vitreous, generally less than 10 hours (del Amo et al., 2015; Kidron
et al., 2012). Hydrophilic small molecules have slightly longer half-lives, up to
~30 h.  The half-lives of  macromolecules,  such as proteins,  are much longer
than those of small molecules, in the range of several days (Krohne et al., 2012;
Zhu  et  al.,  2008).  Intravitreal  delivery  of  small  molecules  as  such,  without
sustained drug delivery systems, is not feasible because of the fast clearance,
but protein drugs that have much longer half-lives (e.g. anti-VEGF agents
ranibizumab and bevacizumab) can be delivered as such.
The volume of distribution is dependent on the relationship between the
total and the free concentration of the drug; binding of the drug in the tissue
increases  the  apparent  volume  of  distribution.  The  volumes  of  drug
distribution in the rabbit vitreal cavity are comparable to the anatomical
volume of the vitreous (del Amo et al., 2015). Therefore, the surrounding
tissues do not have a considerable effect on Vd, as their volume is negligible
compared to the volume of the vitreous and they are also routes of elimination
from the  vitreous.  The  vitreous  contains  proteins,  mainly  albumin,  and  the
total  protein  concentration  is  estimated  to  vary  between  0.5  and  1.5  mg/ml
(Angi et al., 2012; Theocharis et al., 2002; Ulrich et al., 2008). Even though
this  is  much  lower  than  the  protein  concentration  in  the  plasma  (60-80
mg/ml),  it  is  possible  that  drugs  bind  to  these  proteins,  affecting  the
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elimination  and  level  of  free  drug  in  the  vitreous.  Drugs  might  also  bind  to
other components of the vitreous. The data on vitreal binding is sparse; a few
studies have shown unbound fractions from 90 to 99% (Petternel et al., 2004;
Schauersberger  and  Jager,  2002),  suggesting  that  vitreal  binding  is  an
insignificant factor in vitreal distribution. More data of this matter, however,
is needed to understand its full effect.
2.2 TREATING DISEASES OF THE POSTERIOR EYE
SEGMENT
The most serious and prevalent vision-threatening diseases of the eye are the
ones of the posterior segment tissues. As mentioned earlier, the aging
population  is  projected  to  remarkably  increase  the  global  prevalence  of
posterior segment diseases, such as AMD. Treating the posterior segment is
thus of increasing interest worldwide.
2.2.1 DISEASES OF THE POSTERIOR SEGMENT
Many of the diseases of the posterior segment of the eye are related to aging,
but there are also hereditary dystrophies and ocular infections that exist in the
posterior eye.
AMD, the leading cause of blindness in developed countries, is a result of
break-down of  the  macula,  the  most  important  area  of  the  retina  for  visual
acuity. It is characterized by the formation of drusen (debris), constituting of
various lipids, polysaccharides and glycosaminoglycans, under the RPE
(Crabb  et  al.,  2002;  Remington,  2012).  RPE  cells  above  the  drusen  are
eventually lost and cell death of retinal photoreceptor cells follows overlying
the drusen (Ding et al., 2009). AMD can be divided into wet and dry forms. In
the wet, neovascular form (wAMD), the capillaries of the choroid grow into the
retina through the RPE caused by excessive production of angiogenic growth
factors. The dry form does not portray neovascularization, and the formation
of drusen is the main characteristic. Of all AMD cases, 10-20% are of the wet
form, which progresses much faster than the dry form (Tuuminen et al., 2017).
This form can be treated with anti-angiogenic therapies, e.g. antibodies, such
as ranibizumab and bevacizumab, or VEGF-trap aflibercept.
Diabetic retinopathy, caused by hyperglycemia leading to degeneration of
endothelial cells and thickened retinal capillaries, is a common consequence
of diabetes (Cheung et al., 2010). It is characterized by an imbalance in growth
factor production that causes angiogenesis. In some cases, the disease can be
treated with the above-mentioned anti-angiogenic drugs. Retinopathy is found
in up to 80% of patients who have suffered from diabetes for more than 20
years (Stefánsson et  al.,  2000).  The prevalence of  DR is  much smaller  than
that of  AMD, with an estimated 4.2 million patients globally,  but DR is  the
leading  cause  of  blindness  in  the  working-aged  population  (20-74  years)  in
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many industrialized countries, for example in the USA (Cheung et al., 2010).
Although the prevalence of diabetes is increasing, the incidence of retinopathy
in diabetes patients has been shown to decrease, demonstrating the
importance of glycemic control in preventing DR (Klein et al., 2009). Diabetic
macular edema (DME), another complication of diabetes, is characterized by
inflammation and swelling of the macula due to fluid build-up below the retina
(Klaassen et al., 2013). It is less prevalent than DR (Cheung et al., 2010). DME
is  mainly  treated  by  inflammation  reducing  intravitreal  corticosteroids,  but
also with the above-mentioned anti-antiogenic therapies.
Retinitis pigmentosa (RP) is a group of heterogeneous genetic retinal
disorders that cause death of retinal rod cells responsible for peripheral vision
(Dias et al., 2017). It is characterized by the formation of pigmented deposits
in the retina. Overall, RP affects about 2.5 million people world-wide. There is
no commonly used effective treatment for the disease, but gene therapy seems
to  be  the  most  promising  approach.  Voretigene  neparvovec  (Luxturna),  an
RPE65 gene  therapy,  was  recently  approved  for  the  treatment  of  RP (FDA,
2017).
Glaucoma can affect the ganglion cell functions in the retina and thereby
impair the vision (Schwartz and Budenz, 2004). Glaucoma is usually
associated with increased intraocular pressure (IOP) that can cause damage to
the optic nerve. Therefore, the symptomatic treatment of glaucoma is based
on the reduction of IOP by controlling either the formation or turnover of the
aqueous humor. This does not necessarily prevent functional impairment in
the  retina,  and  glaucoma  is  not  always  associated  with  elevated  IOP  (i.e.
normotensive glaucoma). Neurotrophic compounds are needed to improve the
treatment of glaucoma by maintaining the retinal health of glaucoma patients
(Johnson et al., 2011; Nafissi and Foldvari, 2016). The prevalence of glaucoma
is slightly less than that of AMD, with an expected 76 million cases globally in
2020 (AMD 200 million) (Tham et al., 2014).
Uveitis,  an  inflammation  of  the  uvea,  can  be  caused  by  various  disease
conditions (e.g. sarcoidosis, hereditary syndromes) as well as infections (e.g.
herpes virus, toxoplasmosis) (de Smet et al., 2011). It can be a condition of the
anterior  or  the  posterior  segment,  or  both.  The  causes  vary  largely,  but  the
treatment aims to reduce inflammation; intravitreal corticosteroids are used
for non-infectious uveitis (NIU) in the posterior segment (de Smet et al., 2011).
In addition to the chronic diseases described above, acute infections
(endophthalmitis)  are  a  problem of  the  posterior  segment.  They  may  result
from surgery, trauma or intravitreal injection, and although rare, they are
severe  infections  that  can  result  in  vision  loss  (Durand,  2017).  The  causing
pathogens vary, and the treatment is planned according to the pathogen. The
antibiotics used in treating these infections are usually administered
intravitreally (Radhika et al., 2014; Spadea, 2014).
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2.2.2 CURRENT STRATEGIES FOR DRUG DELIVERY TO THE
POSTERIOR SEGMENT
As  the  posterior  segment  tissues  are  difficult  to  reach  at  therapeutic
concentrations with topical drug delivery, the current retinal treatments are
based on intravitreal injections (del Amo and Urtti, 2008). Delivery through
other  routes  is  under  investigation  and  some  delivery  approaches,  such  as
microinjection  to  the  suprachoroidal  space,  are  already  in  clinical  trials
(Pearce et al., 2015).
The first intravitreal drug implant was approved by the United States Food
and  Drug  Administration  (FDA)  in  1996;  a  ganciclovir  implant  for  the
treatment of cytomegalovirus infection in AIDS patients (Vitrasert, Chiron). It
is a polymer-based non-biodegradable implant, designed to release the drug
for 5-8 months (Anselmo and Mitragotri, 2014). Other controlled-release
products and injectables have since been accepted by the regulatory agencies
(Table 1). Small molecular drugs are delivered generally as implants (del Amo
and Urtti, 2008); some of the implants can be injected (with a specific device
accompanying the implant), and some require surgical implantation (Table 1).
Macromolecules,  such  as  anti-VEGF  antibodies,  due  to  their  low  clearance
from  the  vitreous,  can  be  delivered  as  injectable  solutions  without  a  long-
acting delivery system. The most problematic are intravitreal small-molecule
antibiotics for endophthalmitis, as they are rapidly cleared from the vitreous
(Radhika  et  al.,  2014),  and  for  the  large  variety  of  antibiotics,  there  are  no
commercial  long-acting  delivery  systems  on  the  market.  Because  of  the
invasiveness of intravitreal delivery, long-acting delivery systems and
sustained treatment strategies are needed for the therapy of posterior segment
diseases.
Several sustained release approaches for retinal drug delivery are currently
under  development  and  in  clinical  trials  (Pearce  et  al.,  2015).  For  example,
encapsulated  cells  have  been  prepared  for  continuous  production  of  ciliary
neurotrophic factor to decrease the loss of photoreceptor cells (Renexus,
Neurotech (Birch et al., 2013)). A refillable reservoir, inserted through the
sclera into vitreous is being developed for the prolonged delivery of anti-VEGF
antibodies (Port Delivery System, ForSight Vision4 (Rubio, 2014)). In
addition, a micropump, attached below the episclera, has been developed for
prolongation of drug dosing intervals (MicroPump, Replenish (Gutiérrez-
Hernández et al., 2014)). These approaches are capable of delivering a variety
of drugs in a controlled manner even for years, thereby reducing the number
of  invasive  procedures  during  the  clinical  drug  treatment.  Other  methods
being investigated for less-invasive delivery to the posterior segment include
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Table 1. Intravitreal treatments for diseases of the posterior eye segment.
Therapy Delivery system and
administration
Indication Dosing interval/
Time of effect
Vitrasert
(ganciclovir)
Implant, surgical
administration
Cytomegalovirus infection
in AIDS patients
5-8 months
Retisert
(fluocinolone
acetonide)
Implant, surgical
administration
NIU 30-36 months
Ozurdex
(dexamethasone)
Implant, injected Retinal vein occlusion,
NIU, DME
Up to 6 months
Iluvien
(fluocinolone
acetonide)
Implant, injected DME Up to 36 months
Lucentis
(ranibizumab)
Solution, injected wAMD, DR, DME 4-6 weeks
Avastin
(bevacizumab)
Solution, injected Off-label use for wAMD* 4-6 weeks
Eylea (aflibercept) Solution, injected wAMD, DR, DME 4-8 weeks
Intravitreal
antibiotics1
Amikacin
     Ceftazidime
     Vancomycin
Solution, injected Endophthalmitis
   Aerobic, gram-
negative bacteria
   Gram-positive, MRSA
24-96 h
24-48 h
48-72 h
72 h
* Originally approved for colorectal cancer. 1 (Radhika et al., 2014)
MRSA, methicillin-resistant Staphylococcus aureus
delivery to the suprachoroidal space (lamina fusca) with hollow microneedles
(Clearside Biomedical, Inc.) or with a microcatheter (iTrack, iScience
Interventional (Tetz et al., 2012)). The active status of research in delivery
approaches to the posterior segment of the eye demonstrates the need for
developing new strategies to improve the therapy of many vision-threatening
diseases. The variety of drug delivery strategies described above is not meant
as  a  comprehensive  list,  but  as  a  means  to  shed  light  on  the  many
developmental approaches to improve the therapy of the posterior eye
segment.
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2.3 MELANIN PIGMENT
Many drugs accumulate in pigmented tissues,  a  phenomenon that has been
acknowledged for long (Larsson, 1993; Potts, 1964, 1962). The accumulation
is a result of drug binding to melanin. Certain ocular tissues are very densely
pigmented providing plenty of binding opportunities for melanin binding
drugs. Thus, the pigmentation has particularly extensive effects on
pharmacokinetics in the eye.
The biological functions of melanin are still not fully understood, although
many of its effects have been acknowledged. Melanin absorbs visible and UV
light, thus protecting pigmented tissues from the harmful effects of the
radiation (Hu et al., 2008). In the eye, the absorption of light improves image
quality,  as  it  decreases  the  reflection  of  light  from  the  posterior  segment
tissues. Melanin also acts as an antioxidant by scavenging free radicals and
preventing the formation of reactive oxygen species (Bustamante et al., 1993).
It  binds  many  endogenous  and  exogenous  chemicals  (Ings,  1984;  Larsson,
1993; Potts, 1964), participates in metal homeostasis (Hong and Simon, 2007)
and thus protects the tissues from the harmful effects of these substances.
2.3.1 MELANIN AND MELANOSOMES
Melanin  is  a  polyanionic  polymer  located  in  the  pigmented  cells,  inside
intracellular organelles called melanosomes. Melanin can be divided into two
types,  eumelanin  and  pheomelanin,  based  on  its  molecular  structure.  Both
forms have a common precursor, dopaquinone, oxidized from tyrosine
through spontaneous and enzymatic reactions (Figure 3) (Ito and Wakamatsu,
2008; Prota, 1980). In melanogenesis, dopaquinone will be further converted
to dihydroxyindole (DHI)-derived subunits that form eumelanin and sulfur-
containing benzothiazine-derived subunits for pheomelanin synthesis.
Eumelanin  is  black/brown  and  pheomelanin  of  lighter  reddish/yellowish
color.
27
Figure 3 Melanin synthesis and the structure of melanin (modified from (Rimpelä et al.,
2017)). Enzymes involved in the synthesis: tyrosinase and dopachrome
tautomerase (DCT). DHI, dihydroxyindole; DHICA, dihydroxyindole carboxylic acid;
IQ, indolequinone; IQCA, indolequinone carboxylic acid.
Eumelanin  is  more  predominant  in  ocular  tissues  (see  2.3.2  Melanin
containing  tissues)  and  it  is  more  important  for  ocular  melanin  binding  of
drugs. The structure of eumelanin is heterogeneous and its supramolecular
structure is  still  debated (Meredith and Sarna,  2006).  As mentioned above,
eumelanin is formed of DHI-derivatives. These subunits can be quinones or
semi-quinones  and  carboxylated  or  non-carboxylated  (Figure  3),  and
moreover, they are oligomerized through different positions of the subunit
molecules, bringing heterogeneity to the molecular structure of eumelanin.
Rather  than  being  a  linear  polymer  formed of  these  subunits,  eumelanin  is
proposed to be formed of oligomers of 4-8 subunits that are stacked as sheets
with inter-planar spaces of  3-4 Å (Watt  et  al.,  2009; Zajac et  al.,  1994).  For
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drug binding, melanin represents a surface rather than binding pockets. A
detailed  structure  of  melanin  would  benefit  the  understanding  of  drug-
melanin binding.
Melanosomes are intracellular organelles containing the melanin pigment.
Melanin is, therefore, surrounded by a lipid membrane, and it is attached to a
protein matrix in the core of the melanosome. Melanosomes bear a
resemblance to lysosomes; both share proteins related to, for example,
organelle acidification and enzyme digestion, and melanosomes are expected
to have a similar acidic pH as lysosomes (Raposo and Marks, 2009).
The  lipid  composition  of  melanosomes  has  been  characterized  in  bovine
ocular melanosomes (Ward and Simon, 2007). There were differences in uveal
and  RPE  melanosomes,  sphingomyelin  being  the  major  melanosomal  lipid
component in the uvea and glycerophosphoethanolamine in the RPE. Uveal
and RPE melanosomes also differ  in shape;  uveal  melanosomes are smaller
and round and RPE melanosomes larger and more ellipsoid.
Azarian et al. (2006) characterized the protein content of mature porcine
RPE melanosomes identifying 102 proteins related to, for example,
melanogenesis, organelle acidification, proteolysis and transporter and
channel  functions.  MRP4  was  the  only  drug  transporter  found  in
melanosomes, although some other transport-related proteins were present.
More detailed information of melanosome proteome would enable a better
understanding of the effect of melanosomal environment in melanin binding
and pharmacokinetics.
The pH inside ocular melanosomes is expected to be acidic, but only the pH
of  non-ocular  melanosomes  has  been  characterized  (Ancans  et  al.,  2001;
Bhatnagar et al., 1993; Fuller et al., 2001). B16 murine melanoma cells have
been  determined  to  have  melanosomes  with  intraluminal  pH  of  3.0-4.6
(Bhatnagar et al., 1993). Skin melanosomes have also been found to be acidic,
although  a  melanosomal  neutral  pH  has  been  observed  in  dark-skinned
individuals  (Ancans  et  al.,  2001;  Fuller  et  al.,  2001).  Melanin  synthesis  is
proposed  to  be  the  most  efficient  at  near  neutral  pH  where  the  activity  of
tyrosinase  is  the  highest  (Ancans  et  al.,  2001;  Ito  and  Wakamatsu,  2008).
Measuring melanosomal pH, however, is difficult, because fluorescence-based
methods are hampered by the light absorption by melanin. Knowing the pH of
ocular melanosomes would, nevertheless, be important for a deeper
understanding of the drug-melanin binding environment.
2.3.2 MELANIN CONTAINING TISSUES
Melanin pigment can be found in various parts of the body; in the eye, brain
(substantia nigra and locus coeruleus), inner ear, skin, hair follicles and hair
(Dubey  &  Roulin  2014).  Melanin  containing  cells  are  generally  called
melanocytes, and they are dendritic cells. In the eye, melanocytes are present
in the choroid and in the stromas of the iris and ciliary body. Ocular pigment
epithelial (iris, ciliary body and retinal pigment epithelial) cells are of different
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embryonic origin than other pigmented cells, are structurally different
(polygonal cells), and are therefore not called melanocytes.
The amount of melanin in different parts of the body varies, but the eye is
the most densely pigmented organ (Watts et al. 1981). Melanin content in the
tissues can also vary between individuals,  as  for  example skin pigmentation
has  clear  racial  differences.  Melanin  content  of  ocular  tissues  varies  due  to
differences in eye color; lighter colored eyes have generally less melanin (35.2
± 0.9  mg/g  of  uveal  tract  in  blue  eyes  vs.  42.8  ±  1.6  mg/g  of  uveal  tract  in
brown eyes (Menon et al., 1992)). The RPE shows gradually lowering levels of
pigmentation  in  the  aging  eyes  (Feeney-Burns  et  al.,  1984;  Schmidt  and
Peisch,  1986),  but  racial  differences  in  the  amount  of  melanin  are  minimal
(Weiter et al., 1986). The amount of melanin in the RPE does not vary with eye
color  (Schmidt  and  Peisch,  1986),  but  the  total  amount  of  melanin  in  the
posterior eye segment (RPE and choroid) is larger in darker-colored eyes (6.7
mg of melanin/tissue in blue eyes vs. 8.4 mg/tissue in brown eyes) (Menon et
al., 1992).
Melanoma tumors constitute a special type of melanin containing tissue.
Melanoma is generally caused by excessive UV radiation that causes cancerous
changes in the skin melanocytes. These cancerous cells can metastasize
throughout the body. Melanoma cells are very densely pigmented, having even
higher pigmentation than ocular tissues (Borovanský & Riley 2011). The high-
density pigmentation can be used for targeting melanin-binding agents to the
tumors (Link et al. 1989).
In the eye, melanin can be found in the stromas of the iris, ciliary body and
choroid and in the epithelia of the iris, ciliary body and retina (Figure 4). These
tissues  form  a  melanin-containing  envelope  around  the  eye.  According  to
Menon et al. (1992) ~60% of ocular melanin is in the RPE-choroid, and both
the ciliary body and iris contain ~20% of the total ocular melanin.
The epithelial  melanin is  mainly eumelanin (Ito et  al.,  2013;  Prota et  al.,
1998). Melanocytes in the uveal stroma contain both eumelanin and
pheomelanin and their ratio seems to correlate with the color of the iris, with
more eumelanin in dark-colored eyes (Wakamatsu et al., 2008). The turnover
of melanin in ocular tissues is very low; in the RPE, melanin synthesis takes
place mainly during embryogenesis and ceases by two years of age (Boulton,
1998). Since melanin synthesis in negligible after birth, the amount of melanin
in the RPE decreases with age (Feeney-Burns et al., 1984; Weiter et al., 1986).
The melanin content in the RPE of the age group 81-97 was ~40% of that of
the age group 14-40.
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Figure 4 Melanin in ocular tissues. (IPE, iris pigment epithelium; PCE, pigmented ciliary
epithelium.) Figure from Rimpelä et al. (2017), reprinted with permission from
Elsevier.
2.3.3 MELANIN BINDING OF DRUGS AND ITS IMPLICATIONS IN
OCULAR DRUG DELIVERY
Melanin  binding  of  drugs  is  of  interest  in  drug  development,  as  it  is  a
surprisingly common phenomenon. The first indications of drug-melanin
binding  arose  already  in  the  late  1950s  when  the  accumulation  of
phenothiazine  drugs  to  the  pigmented  ocular  tissues  of  animals  was
discovered (Potts, 1962). These drugs were administered systemically and
their  ocular  accumulation  was  an  unexpected  event  at  the  time.  Since  the
recognition of pigment binding as the reason for the accumulation, it has been
shown that long retention times, even up to a year after a single systemic dose
(shown with chloroquine), are possible (Larsson, 1993; Rosenthal et al., 1978).
Since  then,  a  wide  selection  of  compound  groups,  e.g.  beta-blockers,
antimalarials, antibiotics, antidepressants, anesthetics and
sympathomimetics, have been discovered to contain melanin-binding drugs.
Drug development can, therefore, benefit broadly of a deeper understanding
of drug-melanin binding.
Although  a  wide  variety  of  molecular  structures  can  bind  to  melanin
pigment, it has been shown that practically all lipophilic and basic drugs bind
to  melanin  to  some extent  (Leblanc  et  al.,  1998;  Reilly  et  al.,  2015).  This  is
expected, as melanin is a polyanionic and hydrophobic structure. Binding
interactions related to drug-melanin binding include hydrophobic interactions
and electrostatic interactions, including hydrogen bonding and charge
transfer interactions (Kaliszan et  al.,  1993;  Lowrey et  al.,  1997;  Reilly  et  al.,
2015). The molecular features suggested to be relevant for melanin binding are
hydrophobicity, aromaticity, charge-transfer properties and relative positive
charge  (Lowrey  et  al.,  1997;  Reilly  et  al.,  2015).  The  binding  interactions  of
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individual compounds vary, and a general mechanism for binding is unlikely
to exist.
The pharmacokinetic and/or pharmacodynamic effects of melanin binding
of ocular drugs have been shown in many studies.  The most widely studied
drugs include topically applied drugs, such as the anti-glaucoma drugs timolol
and  pilocarpine,  and  the  mydriatic  atropine  (Araie  et  al.,  1982;  Lee  and
Robinson, 1982; Salazar et al., 1976; Salazar and Patil, 1976; Salminen and
Urtti, 1984; Urtti et al., 1984). Ten- to hundred-fold higher concentrations of
timolol  have  been  found  in  pigmented  ocular  tissues  compared  to  the
corresponding albino tissues (Salminen and Urtti, 1984). Similarly, pigmented
tissues have contained up to ten-fold higher concentrations of pilocarpine (Lee
and Robinson, 1982; Salminen et al., 1984). The IOP-decreasing response to
timolol  has been shown to differ  in pigmented and albino eyes as well  as  in
eyes with different colored irides. Despite the higher total concentrations of
the drug in pigmented tissues, the response was lower in pigmented than in
albino animals (Nagata et al., 1993) and similarly lower in dark-colored than
in light-colored eyes (Salminen et al., 1985). This was presumably due to the
reduction in the free drug concentration caused by melanin binding (Salminen
et  al.,  1985).  The  response  to  atropine  and  pilocarpine,  however,  was
prolonged in pigmented animals compared to albino animals, as melanin
forms a depot of the drug from which the drug is released slowly (Salazar and
Patil, 1976; Urtti et al., 1984). It is clear that melanin binding affects the
distribution and pharmacodynamics of binding drugs and that physiological
factors,  such as tissue melanin content,  may affect  the drug response.  For a
more thorough examination of the implications of melanin binding in ocular
drug delivery, the reader is referred to the review section of publication III.
Melanin binding has been investigated also as a desired phenomenon. The
pigmented tissues of the eye are in close proximity to drug targets of both the
anterior and posterior segments of the eye. Targeting melanin could prolong
the  effect  of  a  drug  and  also  target  the  drug  action  to  the  desired  tissues.
Melanin binding was shown to increase the retention of orally administered
pazopanib, a small molecule anti-VEGF agent, in the uveal tract of pigmented
mice  compared  to  albino  mice  (Robbie  et  al.,  2013).  Binding  of  the  drug  to
melanin was thus able to target the drug to the back of the eye, and prolong
the retention of the drug in the posterior segment, showing the feasibility of
this approach in sustaining drug action. More studies are, however, needed to
evaluate the true potential of this strategy in treating ocular diseases.
All in all, it is crucial to understand that the effects of melanin binding on
ocular drug distribution and response are multifaceted, and depend on many
pharmacokinetic factors as well as pharmacodynamic properties of the drug;
drugs that bind to melanin in vitro do not necessarily reach the melanin in the
tissues,  inside  the  intracellular  melanosomes,  and  will  not  bind in vivo
(Larsson  et  al.,  1981);  drugs  for  ocular  and  non-ocular  indications  may
accumulate in the ocular tissues (Potts, 1962); melanin binding may protect
the tissue from too high concentrations of drugs, but potent drugs may cause
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harmful effects because of the accumulation (Leblanc et al., 1998). For these
reasons, it is evident that a deeper, systematic understanding of the interplay
of  different  physiological  factors,  drug  properties  and  melanin  binding  can
benefit the drug development process as well as the understanding of clinical
consequences of drugs accumulating to pigmented tissues.
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3 AIMS OF THE STUDY
The overall aim of the thesis project was to investigate the effect of melanin
and  vitreal  binding  of  drugs  on  their  pharmacokinetics  in  the  posterior
segment of the eye. This was done using in vitro, in vivo and in silico methods.
The specific aims of the thesis were:
1. To find the most suitable binding isotherm to reliably interpret in
vitro drug-melanin binding results for calculating maximum binding
capacity and affinity (I).
2. To evaluate how well cellular level melanin binding can be predicted
from in vitro binding studies with isolated melanin (I, II, IV).
3. To study the interplay of cellular factors and melanin binding on the
retention of drugs in pigmented tissues of the posterior segment of the
eye (II, III, IV).
4. To investigate the effect melanin binding has on intracellular unbound
drug concentrations in the RPE (IV).
5. To study drug binding to the vitreous humor and its effect on vitreal
pharmacokinetics (V).
Overview of the materials and methods
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4 OVERVIEW OF THE MATERIALS AND
METHODS
The materials and methods used in this thesis project are presented in Table
2. More detailed information of the methods can be found in the publications.
Table 2. Overview of the materials and methods.
Study (publication) Method
In vitro studies
Binding of drugs to isolated melanin (I,
II, IV)
Melanin isolation from porcine RPE-choroid
Zeta potential of melanin (II)
Binding assay
UPLC and LC-MS/MS
Calculation of binding parameters (Wolfram
Mathematica and Phoenix WinNonlin)
Studied drugs: Chloroquine, timolol, nadolol, CDCF, methotrexate, propranolol, diclofenac
Cell uptake and elimination (II, IV) Isolation and culturing of porcine primary RPE (pRPE)
cells
ARPE-19 cell culture
Uptake and elimination assays
Melanin content in the cells by spectrophotometry (IV)
UPLC and LC-MS/MS
Studied drugs:
Uptake: Chloroquine, timolol, CDCF (only pRPE), methotrexate, propranolol, diclofenac
Elimination (only in pRPE): Chloroquine, timolol
Binding of drugs to cell homogenate (to
determine intracellular unbound drug
fraction) (IV)
Isolation of pRPE cells
ARPE-19 and pRPE cell culture
Binding assay (rapid equilibrium dialysis)
Melanin content in the cells by spectrophotometry
LC-MS/MS
Studied drugs: Chloroquine, timolol, methotrexate, propranolol, diclofenac
Binding of drugs to the vitreous (V) Isolation of porcine vitreous humor
Binding assay (rapid equilibrium dialysis)
LC-MS/MS
Studied drugs: Cassette mixture of 35 ocular drugs (detailed information in V)
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In vivo studies
Chloroquine kinetics in the eye (II) Radiolabeling of chloroquine with 123I
SPECT/CT of pigmented and albino rats
In silico studies
Cell uptake, unbound fraction, and
intracellular bioavailability predictions
(II, IV)
Calculations in Excel
Kinetic simulations of melanin binding
(III)
Stella software
QSAR modeling (III) KNIME, RDKit, Simca-P software
Kinetic simulations of vitreal binding (V) Stella software
CDCF, 5(6)-carboxy-2?,7?-dichlorofluorescein; LC-MS/MS, liquid chromatography-tandem mass
spectrometry; QSAR, quantitative structure-activity relationship; SPECT/CT; single photon emission
computed tomography/computed tomography; UPLC, ultra-performance liquid chromatography
Publication I: Interpretation of ocular melanin drug binding assays. Alternatives to the model of
multiple classes of independent sites
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5 PUBLICATION I: INTERPRETATION OF
OCULAR MELANIN DRUG BINDING
ASSAYS. ALTERNATIVES TO THE
MODEL OF MULTIPLE CLASSES OF
INDEPENDENT SITES
Reprinted with permission from Manzanares J, Rimpelä A-K, Urtti A:
Interpretation  of  ocular  melanin  drug  binding  assays.  Alternatives  to  the
model  of  multiple  classes  of  independent  sites.  Mol  Pharmaceutics  13  (9):
1251-1257, 2016. © American Chemical Society 2016
Publication II: Drug distribution to retinal pigment epithelium: studies on melanin binding,
cellular kinetics, and single photon emission computed tomography/computed tomography
imaging
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6 PUBLICATION II: DRUG DISTRIBUTION
TO RETINAL PIGMENT EPITHELIUM:
STUDIES ON MELANIN BINDING,
CELLULAR KINETICS, AND SINGLE
PHOTON EMISSION COMPUTED
TOMOGRAPHY/COMPUTED
TOMOGRAPHY IMAGING
Reprinted  with  permission  from  Rimpelä  A-K,  Schmitt  M,  Latonen  S,
Hagström  M,  Antopolsky  M,  Manzanares  J,  Kidron  H,  Urtti  A:  Drug
distribution to retinal pigment epithelium: studies on melanin binding,
cellular  kinetics,  and  single  photon  emission  computed
tomography/computed  tomography  imaging.  Mol  Pharmaceutics  13  (9):
2977-2986, 2016. © American Chemical Society 2016
65
7 PUBLICATION III: IMPLICATIONS OF
MELANIN BINDING IN OCULAR DRUG
DELIVERY
Reprinted with permission from Elsevier. Rimpelä A-K, Reinisalo M, Hellinen
L,  Grazhdankin  E,  Kidron  H,  Urtti  A,  del  Amo  E:  Implications  of  melanin
binding  in  ocular  drug  delivery.  Adv  Drug  Deliv  Rev  (In press). © Elsevier
2017
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Publication III: Appendix A
Can be found online at https://doi.org/10.1016/j.addr.2017.12.008
88
Publication III: Appendix B
94
Publication III: Appendix C
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8 PUBLICATION IV: MELANIN TARGETING
FOR INTRACELLULAR DRUG DELIVERY:
QUANTIFICATION OF BOUND AND FREE
DRUG IN RETINAL PIGMENT EPITHELIAL
CELLS
Unpublished manuscript. © Authors 2018
131
9 PUBLICATION V: BINDING OF SMALL
MOLECULE DRUGS TO PORCINE
VITREOUS HUMOR
Reprinted  with  permission  from  Rimpelä  A-K,  Reunanen  S,  Hagström  M,
Kidron H, Urtti A: Binding of small molecule drugs to porcine vitreous humor.
Mol Pharmaceutics (In press). © American Chemical Society 2018
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10 SUMMARY OF THE MAIN RESULTS
The  main  results  of  the  publications  are  summarized  in  Table  3.  For  the
detailed results, the reader is referred to the original publications.
Table 3. The main results of the thesis.
In vitro melanin binding of drugs (I, II, IV)
Suitability of different binding
isotherms for analysis of
melanin binding results
Melanin binding is relatively non-specific and high capacity
binding and should not be represented by the commonly used
specific binding isotherms (i.e. Langmuir isotherm for one or
two binding site classes). The Sips isotherm was more suitable
for calculating maximum binding capacity and affinity, because
it takes into account the non-specific nature of binding.
In vitro binding Basic drugs bound more strongly than acidic drugs (7 drugs
studied). pH affected the binding in vitro, especially in the case
of acidic drugs, which bound more strongly at lower pH (7.4 vs.
5.0).
Studied drugs: Chloroquine, timolol, nadolol, CDCF, methotrexate, propranolol, diclofenac, (I:
metoprolol from (Pitkänen et al., 2007))
Classification model for high and low melanin binders (III)
QSAR modeling A classification model that predicts high and low melanin
binders was built based on literature binding data. The
molecular properties that determined binding were related to
polarizability and electrostatic interactions.
The interplay of melanin binding and cellular factors in the retention of drugs in pigmented
ocular tissues (III)
Kinetic simulations of
pharmacokinetics in the
posterior segment of the eye
The most important factors determining retention in pigmented
tissues were the affinity to melanin and cell membrane
permeability. Ion trapping also increased the retention.
Dissociation rate from melanin played a role with the moderate
model binder (timolol) but not with the high model binder
(chloroquine). Eye color (differences in the amount of melanin)
did not affect drug concentrations in the back of the eye
considerably. The unbound concentration of a high-binding
drug was only a small fraction (0.1-0.01%) of the total drug
concentration in pigmented tissues.
Studied drugs: Chloroquine, timolol (melanin binding parameters in the model)
Summary of the main results
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Cell uptake and elimination (II, IV)
Cell uptake Uptake of the melanin binding drugs was higher in pigmented
pRPE cells than non-pigmented ARPE-19 cells, and similar in
both cells for the drugs that are low/non-binders. The results for
chloroquine varied in the two studies (II, IV), with much lower
than expected uptake in IV.
Elimination from pigmented
pRPE cells
Chloroquine was retained in the pigmented cells (88% left in
the cells after 48 h), but timolol was eliminated faster (more
than 85% eliminated within 6 h).
Studied drugs:
Uptake: Chloroquine, timolol, CDCF (only pRPE), methotrexate, propranolol, diclofenac
Elimination: Chloroquine, timolol
Intracellular unbound drug concentrations in RPE cells (IV)
Intracellular unbound fraction,
fu,cell
In pigmented pRPE cells, fu,cell varied in the range 0.00016-0.73
and the rank order of the drugs studied could be explained with
the drug's affinity to melanin together with lipophilicity. In non-
pigmented ARPE-19 cells melanin affinity did not play a role,
and fu,cell varied in the range 0.017-1.0.
Intracellular bioavailability, Fic Fic was similar in both pRPE and ARPE-19 cells, as is
expected, since binding should not affect Fic. Previously
reported lower values for acidic than basic compounds, were
also encountered here.
Studied drugs: Chloroquine, timolol, methotrexate, propranolol, diclofenac
Predicting cell uptake and intracellular unbound drug concentrations based on in vitro
binding parameters (II, IV)
Cell uptake In general, cell uptake to pRPE cells could be roughly predicted
with melanin binding parameters (chloroquine was an outlier in
the rank order (IV), due to the unexpectedly low uptake). The
correlations were improved when the pH partitioning in acidic
subcellular compartments was included in the predictions.
Unbound drug concentration
(IV)
The rank order of the unbound drug concentrations of the
melanin binding drugs was correctly predicted based on in vitro
binding parameters. When the low/non-binders were added to
the correlation, the rank-order was no longer correctly
predicted, due to other cellular binding of the lipophilic
diclofenac.
Studied drugs: Chloroquine, timolol, methotrexate, propranolol, diclofenac, CDCF (only uptake, II)
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In vivo kinetics of 123I-chloroquine in pigmented and albino rats (II)
Ocular retention 123I-chloroquine was retained in the eyes of the pigmented rats
but not the albino rat after intravenous administration.
SPECT/CT was a suitable imaging method to study melanin-
related ocular retention non-invasively.
Binding of drugs to the vitreous (V)
In vitro binding to the vitreous Drug binding to porcine vitreous humor was relatively low, in
general much lower than melanin binding. Binding varied
between 21 and 74% in the fresh vitreous and between 0 and
64% in the frozen vitreous at the concentration 100 ng/ml (35
drugs studied).
Kinetic simulations Drug binding to the vitreous had only a modest effect on vitreal
pharmacokinetics (AUCfree drug 75-100%, half-lives up to ~3-fold
compared to no binding).
Discussion and future prospects
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11 DISCUSSION AND FUTURE PROSPECTS
Drug delivery to the posterior segment of the eye continues to be a challenge,
as the burden of posterior segment diseases is increasing and less invasive or
longer-acting drug delivery methods are needed to improve the therapy and
decrease the cost of treatment. New strategies to develop drug delivery
systems  and  approaches  for  sustained  action  are  widely  investigated.  Using
melanin  binding  as  a  tool  to  prolong  the  action  and  target  the  pigmented
tissues of  the eye could be a feasible approach in ocular drug delivery.  This
thesis  project  aimed  to  study  the  impact  of  melanin  and  vitreal  binding  of
drugs on their pharmacokinetics in the eye by using in vitro, in vivo and in
silico tools. In the following sections, the relevance of the methods used in this
study as well as the implications of the results and melanin and vitreal binding
in general, will be discussed.
11.1 RELIABILITY AND TRANSLATIONAL VALUE OF THE
METHODS
11.1.1 MELANIN BINDING METHODS
Melanin  binding  of  drugs  can  be  easily  studied in vitro with  isolated  or
synthetic melanin. This interaction, however, only portrays the intrinsic
interaction with melanin and does not consider other features, such as drug
permeability  in  the  melanosomal  and  plasma  membranes  and  other
pharmacokinetic factors. The method is, on the other hand, a simple way to
screen and assess the binding early on in the drug discovery and development
process. Multiple factors must be taken into account in the binding studies.
First, the pH, at which the binding is studied, can affect the results. The pH
values  of  ocular  melanosomes  are  unknown,  and  the  most  relevant  pH  for
binding  studies  can  only  be  speculated.  We studied  melanin  binding  of  five
compounds to isolated porcine RPE-choroidal melanin at pH values 5.0 and
7.4 (publication II). The binding was pH-dependent, especially for the acidic
compounds  with  pKa values  close  to  this  pH  range.  The  results  can  be
explained based on the properties of melanin and the drugs. Melanin is a
negatively charged polymer, with expected pKa values around 4-5 (Klosterman
and Bettinger,  2016),  and  therefore  it  will  bear  less  negative  charges  at  the
lower  pH  than  at  neutral  pH.  Acidic  drugs  will  undergo  a  similar  shift  in
ionization  being  more  neutral  at  the  lower  pH.  Binding  interactions  are
increased at the lower pH environment, because the repulsion of the negative
charges of melanin and the drug is decreased. This was observed in our data:
melanin binding of methotrexate and CDCF was low at pH 7.4, but increased
considerably  at  pH  5.0.  Similar  pH-dependent  binding  has  been  seen  with
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acidic compounds before (Tsuchiya et al., 1987). The basic compounds studied
did not show pH-dependent binding, as their pKa values were much higher
(>9), and their charge would not change significantly in the pH range 5.0-7.4.
Even though the charge density of melanin may change with pH (zeta potential
-17.1 ± 1.1 mV at pH 5.0 and -20.3 ± 0.3 mV at pH 7.4), only minimal changes
in the binding of the basic compounds were seen.
Secondly, melanin binding is relatively non-specific, low affinity and high
capacity binding on a heterogeneous melanin surface. Binding is rarely studied
at concentrations high enough to reach saturation and the binding curves are
extrapolated to estimate maximum binding capacity (Bmax)  and affinity (Kd)
(Koeberle  et  al.,  2003;  Pescina  et  al.,  2012;  Pitkänen  et  al.,  2007).  These
parameters have generally been calculated with Langmuir binding isotherms
for one or two binding site  classes (Koeberle et  al.,  2003; Ono and Tanaka,
2003; Pescina et al., 2012; Pitkänen et al., 2007), where the binding events are
assumed to represent only one or two specific binding energies, portraying
binding of a gas to a homogenous surface, or specific binding, for example drug
binding to a receptor protein. It is more likely that the binding energies on the
heterogeneous  melanin  surface  show  a  distribution  of  values,  because  the
binding  molecules  are  large  and  flexible  compared  to  gas  molecules.  We
considered these aspects and compared the binding parameters calculated
with the Langmuir and Sips isotherms (publication I). The Sips isotherm takes
into  account  the  distribution  of  binding  energies  through  a  heterogeneity
index n. This is in line with the theory of binding on a heterogeneous surface,
and  we  showed  that  the  binding  was  more  reliably  analyzed  with  the  Sips
isotherm.
Thirdly, the source of melanin can affect the results (Koeberle et al., 2003;
Pitkänen et al., 2007). We used only porcine melanin isolated from the RPE-
choroid  (publications  I,  II,  and  IV),  but  other  melanin  types,  especially
synthetic  melanin  and  melanin  from Sepia officinalis are  widely  used  in
binding studies. There are differences in the structure of these melanins,
although the structures are not known in detail. Synthetic melanin, produced
through  oxidation  of  tyrosine,  has  been  shown  to  contain  mainly
uncarboxylated DHI subunits  (Ito,  1986),  while natural  eumelanin contains
both DHI and the carboxylated, dihydroxyindole carboxylic acid (DHICA),
subunits (Figure 3) (Ito, 1986; Pezzella et al.,  1997; Tsukamoto et al.,  1992).
Particle sizes of different melanins as well as differently isolated melanin from
the same source can vary (Liu and Simon, 2003), influencing the surface area
available for binding in the in vitro study. This, in turn, can affect the binding
capacity. Normalizing the binding values to the surface area could help take
this into account (Pitkänen et al., 2007), but this would require measuring the
surface  area  in  all  cases,  which  can  be  laborious  and  require  specific
instrumentation.  Pitkänen  et  al.  (2007)  reported  2-4-fold  higher  binding
(nmol/mg of melanin) of betaxolol and metoprolol to synthetic compared to
isolated bovine ocular melanin. Normalizing the binding to the surface area of
the melanin reduced the difference,  but synthetic  melanin bound also more
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drug per area. They reported higher binding for betaxolol than for metoprolol
when the results with the same melanin were compared. Betaxolol binding to
bovine  melanin  was,  however,  similar  to  metoprolol  binding  to  synthetic
melanin.  This  was  the  case  also  with  the  surface  area  normalized  results.
Therefore, when comparing the results of different drugs, the binding should
be  studied  with  the  same  type  of  melanin  in  the  same  conditions.
Nevertheless, more information is needed on the effect of the surface area and
melanin structure on the binding, especially for improving the comparison of
different in vitro studies.  We chose to study the binding with porcine RPE-
choroidal  melanin  because  our  focus  of  research  is  in  the  posterior  eye
segment, porcine eyes are easily available, and this type of melanin has been
previously used in melanin binding studies (Pescina et al., 2012).
The in silico methods, QSAR and comparable structure-activity
relationship modeling, can be used together with in vitro binding to evaluate
the relevant molecular features in melanin binding. They can also be used to
predict the binding of new compounds, even before they have been
synthesized (in silico screening of compound libraries). Structure-activity
models  have  been  built  of in vitro (Kaliszan et al., 1993; Radwa?ska et al.,
1995; Reilly et al., 2015) and in vivo results (Zane et al. 1990: uveal tract-to-
blood  ratio  of  the  drug  in  pigmented  rats).  The in vitro studies have been
conducted  with  the  traditional  method  (incubating  the  drug  with  the
compound)  or  modified  methods,  such  as  affinity  chromatography  with
melanin immobilized to a high-performance liquid chromatography (HPLC)
column and measuring the retention time of the compound. It is important to
understand that the model will only describe the outcome that is measured,
i.e. retention in a melanin column or traditional in vitro binding.  It  has the
same limitations of in vitro studies as explained above, and only describes the
intrinsic interaction under certain conditions. When in vivo data is used for
the analysis, the outcome the model predicts is closer to the situation in the
body, but the phenomenon predicted here is much more multifaceted and can
add  uncertainty  to  the  model.  Another  concern  of  the  QSAR  approach  is
related to the chemical space of the used compound set (Eriksson et al., 2003).
The  published  models  have  had  only  narrow  chemical  spaces  of  molecular
analogues, and these types of models are not applicable outside their chemical
space.  Because melanin binding is  relatively non-specific,  a  large data set  is
required to build a generalized model. The authors of Pelkonen et al. (2017b)
were not able to build a QSAR model based on the in vitro melanin binding
results of 34 drug compounds studied as a cassette; the compound set had a
relatively  wide  chemical  space,  possibly  affecting  the  failure  to  build  a
quantitative model of a small drug set. Jakubiak et al. (2017) were able to build
a categorizing model with in vitro binding results of 3500 compounds with a
90  %  success  rate  in  categorizing  new  compounds  (model  not  published,
reference from a conference). This shows that large compound sets are needed
to make predictive models of melanin binding. The model built by Reilly et al.
(Reilly  et  al.,  2015)  included  the  data  of  263  compounds,  but  the  model
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equation was not published and, therefore, cannot be used publicly. We aimed
to  build  a  classification  model  that  can  distinguish  between  high  and  low
melanin binders (in vitro), with the purpose of helping to assess the likelihood
of  a  certain  compound  to  bind  to  melanin  (publication  III).  Classification
instead of a purely quantitative approach, simplifies the model, giving an easy-
to-interpret tool for evaluating drug binding to melanin for in silico screening.
Building a quantitative model based on literature data would be impossible,
due to the wide variety of experimental conditions used.
Experiments  with  pigmented  cells  also  take  into  account  the  other
processes involved in melanin binding, such as permeability in the membranes
and melanosomal pH. This approach has been utilized only rarely, and data
from cell uptake studies are scarce. Many continuous cell models, for example
the RPE cell line ARPE-19, are generally non-pigmented at short culture times
(<2  months)  (Ahmado  et  al.,  2011).  Therefore,  the  use  of  primary  cells
containing melanin pigment is justified. We studied drug uptake and
elimination in porcine primary RPE cells (publications II and IV). Porcine eyes
are convenient to use for their easy availability from slaughter houses and the
simplicity of RPE cell isolation. RPE cells, however, do not synthesize melanin
in the normal conditions, and, therefore, the amount of melanin in the ex vivo
cells is distributed between the daughter cells upon cell division. Thus, the
final melanin content will be smaller than in the intact RPE in vivo. Measuring
the amount of melanin in the cells is important when the effect of melanin on
cellular drug uptake or elimination is studied, for a better experimental
comparison  between  different  cell  batches  and  cell  types.  Quantitating  the
amount of melanin can also give insight into the effect the amount of melanin
has on drug uptake. In addition to primary cells from animal eyes, for example
human fetal RPE cells and ARPE-19 cells fed with melanin or melanosomes
can be used (Basu et al., 1989). Melanin and melanosomes are phagocytosed
by ARPE-19 cells and the amount of melanin inside the cells can be controlled
(Rimpelä et al., 2017). These cells were not utilized in the experiments of this
thesis project, but they are promising tools to evaluate pigment related drug
pharmacokinetics at the cellular level.
We employed a method that has been previously used with non-pigmented
cells (Mateus et al., 2017b, 2014, 2013), to study the fraction of unbound drug
in pigmented cells (publication IV). The unbound fraction (and concentration)
of the drug can be considered as the fraction that elicits the drug actions, either
beneficial or adverse. From the pigment targeting and sustained action point
of view, the unbound concentration determines the feasibility of the approach
in a drug-specific manner considering the potency (the concentration that is
required for the effect) of the drug. Therefore, it is important to determine the
unbound fractions of the melanin-binding drugs in the cells. The method used
here entails the incubation of the drug with homogenized cells and measuring
both the free and bound drug. Although the method gives useful information
of the expected unbound fractions, it does not take into account certain
physiological factors, such as intra-melanosomal pH. As a benefit, the method
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informs also of  other,  non-melanosomal binding in the cells.  Therefore,  the
method  is  a  valuable  addition  to  the  arsenal  of  techniques  to  evaluate  the
effects of pigment binding.
Although in vitro binding  studies  and  cell  studies  can  be  useful  tools  in
screening drugs and understanding the intrinsic and cellular level binding, in
vivo studies are required to take into account the full extent of factors affecting
the  binding.  We  demonstrated  the  use  of  SPECT/CT  imaging  in  evaluating
melanin binding related accumulation of intravenously administered 123I-
chloroquine  in  pigmented  and  albino  rats  (publication  II).  This  method  is
noninvasive,  as  the  same  animal  can  be  examined  throughout  the  study.
Studying pigment binding in vivo is generally accomplished by euthanizing
the  animal  at  a  certain  time  point  and  measuring  the  concentration  in  the
tissues  by  other  analysis  methods,  such  as  LC-MS,  HPLC  (Cheruvu  et  al.,
2008; Sauer and Anderson, 1994), or autoradiography (Báthory et al., 1987;
Lindquist,  1973).  These  approaches  require  the  use  of  numerous  animals.
Non-invasive  imaging  methods,  in  contrast,  can  significantly  reduce  the
number of animals needed. Although tissue-specific concentrations cannot be
obtained with the sole SPECT/CT imaging (the resolution does not separate
different tissue segments), drug accumulation to the ocular area can be clearly
monitored. The kinetics in the ocular area can therefore be assessed. A
drawback of this method is the requirement for radiolabeling, a modification
that may potentially affect the melanin binding and other properties of the
drug.
In addition to in vitro and in vivo methods,  we  utilized  modeling  to
evaluate the interplay of melanin binding and cellular and physiological
factors in the pharmacokinetics of the posterior eye segment (publication III).
With  this  method,  we  were  able  to  evaluate  the  effects  of  factors  such  as
permeability in the plasma and melanosomal membranes, amount of cellular
melanin and melanin binding affinity of the drug, on the retention of drugs in
pigmented tissues. This method helps to demonstrate the integrated effects of
multiple  factors  simultaneously  and  to  assess  the  impact  of  individual
parameters.  So far these mechanistic bottom-up simulations have not been
experimentally validated in in vivo studies. In vivo data would help to improve
the model for a wider use in assessing the kinetics of binding.
11.1.2 VITREAL BINDING METHODS
Binding  of  drugs  to  the  vitreous  humor  was  studied  with  fresh  and  frozen
homogenized vitreous from porcine eyes (publication V). The homogenization
process can affect the rheology and composition of the vitreous, as mainly the
soluble components are included in the final fraction. Soluble proteins, such
as  albumin  and  ?1-acid glycoprotein as well as soluble glycosaminoglycans,
components that the drugs could bind to, are expected to be in the final isolate.
Therefore, the method can be assumed to be suitable for studying the binding.
The data on vitreal binding is scarce (Petternel et al.,  2004; Schauersberger
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and Jager, 2002), but based on the low volumes of distribution in the vitreous
reported in literature (del Amo and Urtti, 2015; Kidron et al., 2012) indicating
a low effect of vitreal binding, we can assume the binding analyzed with this
method to be close to reality.
11.2 EFFECT OF BINDING ON PHARMACOKINETICS
11.2.1 INSIGHTS FROM THIS STUDY
This  thesis  project  aimed  to  provide  information  and  increase  the
understanding  of  the  effect  of  melanin  and  vitreal  binding  on  the
pharmacokinetics  of  drugs  in  the  eye.  We  demonstrated  the  usefulness  of
different  methods  to  characterize  drug  binding  to  melanin  and  the  vitreous
humor.  The  results  give  insights  into  the  pharmacokinetic  impact  of  the
binding events.
In vitro binding to isolated or synthetic melanin is generally accepted as
the measure of melanin binding, as it should be, but with certain reservations.
As discussed earlier, the experimental conditions and the source of melanin
may affect the results and the simple binding experiment does not take into
account other physiological processes. We aimed to bridge the gap between in
vitro and  cellular  level  melanin  binding  by  comparing  the  measured  cell
uptake and unbound fractions in pigmented primary RPE cells with values
calculated based on in vitro binding parameters, Bmax, Kd, and n (publications
II and IV). Melanin binding, as expected, did not explain the whole uptake, as
other cellular factors contribute to it, but the rank order of the amount of drug
taken up by the cells was correctly predicted. The correlation was improved,
when the pH partitioning in different intracellular compartments calculated
based on the pKa values of the compounds, was included. Additional factors
that  should  improve  the  correlation  include  binding  to  other  cellular
components, governed mainly by compound lipophilicity (Mateus et al., 2013).
The pharmacokinetic modeling to assess drug retention in the pigmented
tissues also takes into account other cellular and physiological factors that act
in concert with melanin binding (publication III). The most important factors
include melanin binding affinity and capacity (Bmax, Kd, n): the simulations
with  binding  parameters  of  chloroquine  (high  binder)  showed much longer
retention than the simulations with the parameters of timolol (moderate
binder). Cell and melanosome membrane permeabilities also affected the
retention considerably; the lower the permeability, the longer the duration of
the retention. Ion trapping is described by the preferential distribution and
retention of positively charged drugs in the acidic intra-cellular organelles (e.g.
lysosomes).  This  mechanism  may  be  involved  in  the  melanosomal  drug
entrapment:  simulations with lower outward than inward permeability in the
melanosome membrane resulted in increased drug retention in the
melanosomes. The pH of melanosomes is not known, but can be expected to
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be acidic (Ancans et al., 2001; Bhatnagar et al., 1993; Ito and Wakamatsu,
2008).  Therefore,  ion trapping may increase the retention of  basic  drugs in
pigmented cells.
Eye color is related to the differences in the amount and type of melanin
(eumelanin/pheomelanin) in the iris (Eagle, 1988; Wakamatsu et al., 2008).
Based on the simulations (publication III), the amount of melanin in different-
colored eyes had minimal effect on drug retention in the retina-choroid, since
the differences in the amount of melanin in these tissues, are only modest (6.7
mg  in  blue  eyes  vs.  8.4  mg  in  brown  eyes).  However,  the  data  on  melanin
amounts are rather sparse, and definite conclusions of the amount cannot be
made, especially in the case of disease and aging. In the anterior segment of
the eye, in vivo studies in human have shown differences in the response to
timolol  (Salminen  et  al.,  1985),  although  the  difference  in  the  amount  of
melanin in the anterior tissues, iris and ciliary body, seems to be similar as in
the posterior segment (4.2 mg in blue eyes vs. 4.9 mg in brown eyes (Menon
et al., 1992)). Therefore, more data of the effect of the melanin amount in the
tissues are needed.
The pharmacokinetic modeling demonstrated another crucial consequence
of binding; the free concentration is much lower than the total concentration
in the pigmented tissue. The cellular free concentration of the high binder
(chloroquine parameters) was 0.01-0.1% of the total concentration and of the
moderate binder (timolol parameters) 1-10% of the total concentration.
Therefore, the total concentration is not representative of the
pharmacologically relevant drug retention in the tissue. In pharmacokinetic in
vivo studies, the total concentration has generally been measured (Lindquist,
1973;  Ono  et  al.,  2003;  Salminen  et  al.,  1984),  and  it  is  important  to
understand that this differs significantly from the active unbound
concentration.
Although tissue binding and unbound fractions in non-pigmented cells
have been investigated (Mateus et  al.,  2017a,  2013;  Pfeifer  et  al.,  2013),  the
unbound fractions and drug binding in pigmented cells have not been studied
previously. We studied the unbound fractions in pigmented (primary porcine)
and non-pigmented RPE (ARPE-19) cells, demonstrating clear differences due
to melanin binding of the drugs (publication IV). In pigmented RPE cells, the
unbound fraction of chloroquine, the highest melanin binder studied in this
thesis,  was  only  0.02-0.05%  of  the  total  concentration,  while  in  non-
pigmented ARPE-19 cells it was 5-10% of the total. This clearly shows the effect
pigment binding has on the unbound concentration, especially in the case of
extensive binding, and demonstrates the importance of the unbound
concentration in cellular and in vivo studies. With this method, we could also
show, that other cellular binding events, not only melanin binding, decrease
the unbound fraction.
The retention of 123I-chloroquine  in  ocular  tissues  of  pigmented  but  not
albino  rats  was  demonstrated  with  SPECT/CT  imaging  (publication  II).
However,  the  total  concentration  was  measured,  which,  again,  does  not
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represent the effective unbound concentration. The retention of total
chloroquine (free + bound) in pigmented tissues was shown also in the cell
uptake and elimination study. Chloroquine exhibits similar retinal toxicity in
both pigmented and albino animals (Leblanc et al., 1998). This suggests that
the  total  accumulation  of  chloroquine  caused  by  melanin  binding  does  not
increase the toxicity of chloroquine, likely because the unbound concentration
is still relatively low although the duration of retention is longer.
Based on the relatively low vitreal  binding of  the drugs evaluated in this
study  (publication  V),  it  is  likely  that  vitreal  binding  does  not  considerably
affect the pharmacokinetics or pharmacodynamics of small molecule drugs in
ocular tissues. Vitreal binding was much lower than melanin binding; vitreal
free fractions being 26% or higher, compared to pigmented cell free fractions
being as low as 0.02%. According to the kinetic simulations performed based
on the measured vitreal binding, the elimination half-life was increased ~3-
fold in the case of the highest binding (74%) compared to no binding. In this
case, the area under the concentration curve (AUC, of the free concentration)
was decreased to 75% compared to the no-binding scenario, i.e. only a modest
change in drug exposure. Data on vitreal binding, however, are scarce
(Petternel et al., 2004; Schauersberger and Jager, 2002) and more results
could  help  confirm  our  finding  of  the  low  impact  of  binding  on  vitreal
pharmacokinetics. Vitreal binding has, for example, been demonstrated as a
suitable targeting approach to sustain the action of anti-VEGF agents through
hyaluronan-binding peptide moieties (Ghosh et al., 2017), but small molecule
drugs  have  not  been  shown  to  bind  to  the  vitreous  extensively.  We  can
conclude that the broad pharmacokinetic and pharmacodynamic effects
caused  by  melanin  binding  do  not  apply  to  vitreal  binding,  and  it  can  be
construed as a minor factor in ocular pharmacokinetics.
All  in  all,  we  can  summarize  the  main  insights  from our  results  to  be  1)
melanin  binding  explains  cellular  retention,  as  higher  binding  drugs  are
retained  to  a  higher  extent  and  can  be  retained  for  long,  2)  other  drug
properties (lipophilicity, acid/base status and pKa, membrane permeability)
are important features to consider and explain drug distribution to the cells,
3) free concentrations of melanin-binding drugs are much lower than the total
tissue concentration, and emphasis on the free concentration should be given
accordingly,  and  4)  vitreal  binding  plays  a  modest  role  in  ocular
pharmacokinetics.
11.2.2 GENERAL CONSIDERATIONS
As emphasized in the previous chapters, the effect of melanin binding on the
pharmacokinetics is multifaceted. Systemically administered drugs distribute
widely in the body, and may accumulate to many tissues that contain melanin,
depending on the binding properties and membrane permeability of the drug.
The physicochemical properties of the drug determine permeability, and the
drug’s  ability  to  access  melanin  within  the  intracellular  melanosomes.  The
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processes involved in posterior eye segment pharmacokinetics, as related to
drug binding to melanin and the vitreous, are compiled in Figure 5.
Distribution of the drug from the systemic circulation to the tissues is
governed  by  plasma  protein  binding,  membrane  permeability  and  tissue
binding  (Rowland  and  Towzer,  2011).  It  has  been  shown  that  the  unbound
fraction  of  the  drug  distributes  from  the  plasma  to  the  eye;  the  lower  the
plasma protein binding, the higher is the distribution (Vellonen et al., 2016).
In  addition  to  ocular  distribution,  the  drug  can  access  other  melanin
containing tissues and bind to melanin. The eye, however, is the most densely
pigmented organ in the body, and the accumulation to the ocular pigmented
tissues is expected to be the most extensive. Distribution in other melanin
containing tissues has been detected; more extensive drug distribution to the
pigmented  rat  skin  compared  to  non-pigmented  skin  was  seen  with  basic
melanin-binding drugs (comparison of the distribution of 200 structurally
differing compounds) but the distribution of these drugs to pigmented ocular
tissues was still more extensive (Harrell et al., 2015). The higher distribution
to  the  eye  than  other  melanin-containing  tissues  has  been  observed  also  in
other  studies  (Ono et  al.,  2003;  Tanaka  et  al.,  2004).  Melanin  binding  has,
nevertheless, been connected with side-effects in non-ocular melanin-
containing tissues: melanin binding of aminoglycoside antibiotics has been
suggested to be the reason for their ototoxicity (Wrze?niok et al., 2013), dermal
side effects of anthracycline therapy have been considered to depend on
melanin binding (Svensson et al., 2003), and neurodegenerative properties of
the  pesticide  paraquat  and  its  analogue  MPTP  have  been  speculated  to  be
caused by neuromelanin binding in the substantia nigra of the brain (Karlsson
and Lindquist, 2016). More information is, therefore, needed on the
distribution of drugs to non-ocular pigmented tissues and the effects they may
have  in  these  tissues.  Drug  distribution  to  the  other  melanin-containing
tissues  can  be  decreased  by  using  local  routes  of  drug  administration.
Intravitreal delivery, especially, results in higher drug concentrations in the
posterior segment of the eye.
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Figure 5 Insights on ocular pharmacokinetics: impact of factors affecting drug distribution
and retention in pigmented tissues. Melanin binding was the main contributor to
ocular and intracellular distribution of the factors studied (i.e. high impact). Cell
membrane permeability and binding to other cellular components than melanin
affected ocular and intracellular distribution, but to a lesser extent than melanin
binding (i.e. medium impact). Vitreal binding was relatively low and is expected to
have only a modest impact on ocular pharmacokinetics (i.e. low impact).
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After the drug has reached the cells, intracellular distribution influences
the response to the drug (Figure 5). Target location inside the cells and drug
partitioning into different compartments of the cell, such as the melanosomes,
lysosomes and other endosomes, determines the response. Lysosomes may,
for  example,  accumulate  drugs  due  to  the  entrapment  of  positively  charged
compounds  in  their  acidic  lumen  (Nadanaciva  et  al.,  2011).  This  can  cause
harmful  effects,  but  diseases,  such  as  AMD,  that  have  possible  lysosomal
targets  (Kinnunen  et  al.,  2012),  may  also  benefit  from  the  accumulation.
Uncertainty in target  exposure is  one of  the main contributors  to failure in
clinical trials (Cook et al., 2014; Morgan et al., 2012). As many as 100% of the
development programs of compounds where target exposure has not been
verified, have been shown to fail in phase II (efficacy study) of the clinical trials
(Morgan  et  al.,  2012).  Therefore,  it  is  crucial  to  understand  and  investigate
intracellular distribution of drug candidates. The multifactorial mechanisms
involved in drug distribution and melanin binding (Figure 5) demonstrate that
mechanistic understanding of intracellular as well as body-level
pharmacokinetics is of high importance when evaluating the distribution and
effects in pigmented cells.
The  drug  response  in  the  pigmented  tissues  depends  on  the  melanin
binding properties as well as on the pharmacodynamic properties of the drug.
The free concentrations of melanin binding drugs in pigmented tissues can be
very  similar  to  those  in  non-pigmented  tissues,  even  though  the  total
concentration in pigmented tissues is higher. Therefore, the response to the
drug may not be affected even though the distribution is. In general (as seen
in the kinetic simulations of this study, publication III), melanin binding
lowers the maximal cellular free concentration, but the concentrations are
retained  longer.   Toxicity  related  to  melanin  binding  depends  on  the  same
issues described above, i.e. whether the free concentration is sufficient to cause
toxicity and if the duration of the retention affects the toxicity. It has been
clearly shown that melanin binding in ocular tissues does not predict ocular
toxicity (Leblanc et al., 1998), therefore, the toxicological implications need to
be assessed individually for each drug.
There is a possibility of drug-drug interactions related to melanin binding
as  various  compounds  have  been  shown  to  be  displaced  by  other  binding
compounds in in vitro studies (Pelkonen et al., 2017b; Salazar-Bookaman et
al.,  1994;  Testorf  et  al.,  2001).  Competitive  binding  has  also  been  shown to
increase the cytotoxic effects of anthracyclines in vitro; chloroquine displaced
the  melanin-bound  anthracyclines  which  were  able  to  consequently  cause
higher cytotoxicity (Svensson et al., 2003). From the targeting point of view,
being displaced by another drug could hamper the effectiveness of targeting as
the victim drug would be removed from the desired location. Displacement
could, however, also increase the effect as more of the drug would be in the
free form. Drug-drug interactions are, therefore, complex, and can be
beneficial or counterproductive, depending on whether melanin binding
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improves or inhibits the effect and how the other binding drug modulates the
free concentration of the victim drug.
This thesis project studied the impact of melanin binding of small molecule
drugs,  but  many  of  the  posterior  segment  diseases  (e.g.  AMD  and  DR)  are
treated with therapeutic proteins. Macromolecule binding to melanin pigment
has  been  shown  with  cytochrome  c  (12.4  kDa),  which  bound  to  melanin in
vitro and  had  a  permeation  lag  time  related  to  melanin  binding  in ex vivo
sclera-choroid-Bruch’s membrane (Tratta et al., 2014). Therefore, it is possible
that also macromolecules are affected by melanin binding related
pharmacokinetic  effects,  but  due  to  the  poor  cell  membrane  permeation  of
macromolecules,  the restriction of  access to melanin will  most likely hinder
the binding in vivo. More studies are, however, needed to better assess the
impact of melanin binding of macromolecules.
The approach of targeting melanin pigment to achieve sustained action in
the  anterior  and  posterior  segments  of  the  eye  seems  to  be  a  promising
approach, and indications of its feasibility in the posterior eye segment have
already been reported (Robbie et al., 2013). As mentioned above, the eye is the
most  densely  pigmented  organ,  providing  a  basis  of  delivering  drugs
systemically  to  reach  the  pigmented  ocular  tissues  and  avoiding  harmful
accumulation into other pigmented tissues. Melanoma tumors have been
targeted with the approach of delivering melanin-binding radiochemicals and
other cytotoxic agents to the tumor but avoiding their harmful effects in other
pigmented tissues (Link et al., 1989). Melanoma tissue, depending on the type
of melanoma, can be more densely pigmented than the eye (mouse melanoma
0.68 ± 0.13% melanin by weight vs.  mouse eye 0.40 ± 0.02% (Watts et  al.,
1981)), and a similar principle is applied there as would be in ocular targeting
through systemic delivery; the drug can be targeted to the most densely
pigmented tissue and too high concentrations in the less pigmented tissues
can be avoided. Another important notion benefiting the approach of targeting
through  systemic  delivery,  is  that  melanin  binding  does  not  correlate  with
plasma  protein  binding  (Pelkonen  et  al.,  2017b).  This  can  ensure  a  large
enough  distribution  of  melanin-binding  drugs  to  ocular  tissues  from  the
systemic circulation, as the plasma protein binding is not increased in the
same proportion with melanin binding.
11.3 RELEVANCE FOR DRUG DEVELOPMENT
Drug discovery and development processes are daunting tasks lasting for more
than  a  decade  in  average  for  each  new  drug  molecule.  The  cost  has  been
estimated to be even $5 billion per drug (Herper, 2012). Typically about 90%
of the compounds that reach clinical phases fail before market authorization.
More efficient preclinical drug discovery and development methods are
constantly investigated to improve the success rate in the clinical phases and
overall  drug  development.  Recently,  a  lot  of  attention  has  been  paid  to
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computational methods to alleviate the costs of experimental studies and to
predict the efficacy and safety of the compounds in man (Jones et al.,  2015;
Sliwoski  et  al.,  2014).  Moving  towards  computational  methods  is  also  in
accordance  with  the  principle  of  the  three  R’s;  reduction,  refinement,  and
replacement of animal studies in research. These methods include
pharmacokinetic and pharmacodynamic modeling as well as quantitative and
mechanistic  modeling  of  interactions  of  drug  molecules  with  different
components (receptors, other proteins, cell membranes, DNA etc.) of the body.
This study delivers new computational  methods on melanin binding and its
pharmacokinetic implications, for the use in drug discovery and development.
For  the  development  of  drugs  with  non-ocular  targets  and  indications,
accumulation  to  the  pigmented  ocular  tissues  is  considered  to  be  a  burden.
The possibility of toxicity related to retinal drug accumulation may be
considered  as  too  high  a  risk  to  take  and,  therefore,  the  analogues  without
accumulation are preferred in drug development. Since new drug candidates
tend  to  be  more  lipophilic  than  before  (Leeson  and  Springthorpe,  2007),  a
feature that also promotes melanin binding, there is a prospect for increased
melanin  binding  of  drug  candidates  in  the  future.  The  QSAR  classification
model built in this study can be used to evaluate melanin binding already at
the drug discovery phase to assess if the molecule is classified as a high binder.
The  molecules  shown  as  high  binders,  can  in  turn  be  tested  with in vitro
methods (in vitro binding, cell uptake) to assess the extent of binding.
With binding parameters from in vitro studies, the pharmacokinetic model
built  in  this  thesis  project  offers  another  tool  to  predict  the  retention  of
melanin  binding  drug  candidates  in  the  pigmented  tissues.  The  model  can
incorporate measured or predicted parameters regarding melanin binding,
cellular permeability, ionization inside acidic compartments (ion trapping) as
well as macroscopic pharmacokinetic parameters (clearance, volume of
distribution) in the vitreous and in the systemic compartment. Therefore, the
model  reported  here  can  easily  be  used  in  early  screening  in  the  drug
development process.
For the realization of the approach of targeting melanin to obtain sustained
action in the pigmented ocular tissues, the unbound fraction of the drug plays
a crucial role. Assessing the unbound fractions in pigmented cells in a high-
throughput manner during the drug development process would enable the
screening of compounds in regard to whether the unbound concentration is
sufficient to elicit the drug response. The cell homogenate binding method
employed in this study has already been used with a screening capacity of 1000
compounds per week with non-pigmented cells from different sources
(Mateus et al., 2017a). Using pigmented cells would require a continuous cell
source where pigmentation is at the level of in vivo pigmentation in a
reproducible manner. Isolated primary RPE cells do not fill these criteria,
therefore, different cell sources, such as melanin-fed ARPE-19 cells (Basu et
al.,  1989; Rimpelä et  al.,  2017) or stem cell  derived RPE cells  (Sorkio et  al.,
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2014), should be explored for this purpose. Nevertheless, this method offers a
possibility for the rapid evaluation of the unbound fractions.
11.4 FUTURE PROSPECTS
This  study  provides  new  information  on  the  effects  of  cellular  processes  in
melanin binding, but a more systematic understanding of drug-melanin
binding interactions and interplay of cellular and physiological factors would
enable a more thorough conception of the factors driving the binding.
The  pH  of  ocular  melanosomes  still  remains  unknown  and  the
environment  where  the  binding  takes  place  is  not  fully  characterized.  To
improve the understanding acquired from in vitro studies with melanin and
to optimize the binding conditions to correlate with the in vivo situation, more
detailed  information  about  the  pH and the  composition  of  melanosomes  as
well as the surface area of melanin is needed. Studying the interactions with
melanosomes instead of melanin is another option, but the isolation of intact
melanosomes is more laborious (Pelkonen et al.,  2016) than the isolation of
melanin or RPE cells. Thus, studying the binding in whole cells would better
assess the interactions in the physiological environment. Furthermore, cell
models with a continuous pigmentation comparable to in vivo pigmentation
would  simplify  the  methods  of  studying  cellular  binding,  uptake  and
elimination.
According to the principle of the three R’s, and in search of more efficient
drug development methods, creating a well-validated ocular pharmacokinetic
model would be of great benefit. As melanin binding is an important factor in
ocular pharmacokinetics, it should be included in the model with an accurate
representation. The pharmacokinetic model could eventually be widened to a
PK/PD model, portraying the pharmacodynamic (PD) effect together with the
pharmacokinetics (PK). This kind of a model could help in assessing beneficial
effects of melanin binding as well as toxicological implications.
Regarding the melanin targeting approach, there are still many hurdles to
overcome.  In  addition  to  the  more  systematic  understanding  of  melanin
binding and the interplay of other factors with melanin binding, the feasibility
of  this  approach  regarding  its  safety  and  efficacy  aspects  still  needs  to  be
demonstrated. When this is accomplished, the approach could be used in the
treatment of a multitude of diseases with new melanin binding drugs as well
as melanin targeting fragments conjugated to existing effective drugs.
Conclusions
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12 CONCLUSIONS
This thesis focused on investigating the impact of melanin and vitreal binding
of drugs on their pharmacokinetics in the eye. The following conclusions can
be drawn from the results of this study:
1) Basic drugs have higher in vitro binding to melanin than acidic drugs,
due to electrostatic interactions. The in vitro binding environment (pH,
concentrations of melanin and the drug), however, has a clear effect on
drug-melanin binding.
2) The Sips binding isotherm is more suitable for the analysis of melanin
binding parameters than the generally used Langmuir binding
isotherms, because it takes into account the distribution of binding
energies likely to be encountered in melanin binding.
3) Intracellular unbound concentrations of melanin-binding drugs are
much  lower  than  the  total  intracellular  concentration,  and  the  total
concentration does not necessarily translate into drug response.
4) In vitro melanin binding parameters can explain cellular uptake and
unbound intracellular fractions of drugs, together with other
parameters, such as drug lipophilicity and acid/base status.
5) The interplay of cellular factors with melanin binding is crucial in ocular
pharmacokinetics. Cell and melanosome membrane permeabilities and
ion trapping into acidic subcellular compartments, in addition to
melanin affinity, affected the retention of drugs in pigmented tissues of
the posterior segment of eye (RPE-choroid), based on kinetic modeling.
6) Melanin binding retains drugs in pigmented tissues. The high melanin-
binding  drug,  chloroquine,  was  retained  in  ocular  tissues  of  a
pigmented  rat,  but  not  albino  rat.  Similar  retention  was  seen  in
pigmented RPE cells in vitro.
7) SPECT/CT imaging is a suitable method to monitor melanin binding
related ocular drug distribution and retention in pigmented rats.
8) Vitreal  binding  of  small  molecule  drugs  is  a  less  significant  factor  in
ocular pharmacokinetics than melanin binding, as vitreal binding of 35
clinical drugs was found to be relatively low.
161
REFERENCES
Ahmado, A., Carr, A.-J., Vugler, A.A., Semo, M., Gias, C., Lawrence, J.M.,
Chen, L.L., Chen, F.K., Turowski, P., da Cruz, L., Coffey, P.J., 2011.
Induction  of  Differentiation  by  Pyruvate  and  DMEM  in  the  Human
Retinal Pigment Epithelium Cell Line ARPE-19. Invest. Ophthalmol. Vis.
Sci. 52, 7148.
Ahmed, I., Patton, T.F., 1985. Importance of the Noncorneal Absorption Route
in  Topical  Ophthalmic  Drug  Delivery.  Invest.  Ophthalmol.  Vis.  Sci.  26,
584–587.
Ancans, J., Tobin, D.J., Hoogduijn, M.J., Smit, N.P., Wakamatsu, K., Thody,
A.J., 2001. Melanosomal pH controls rate of melanogenesis,
eumelanin/phaeomelanin ratio and melanosome maturation in
melanocytes and melanoma cells. Exp. Cell Res. 268, 26–35.
Angi, M., Kalirai, H., Coupland, S.E., Damato, B.E., Semeraro, F., Romano,
M.R., 2012. Proteomic analyses of the vitreous humour. Mediators
Inflamm. 2012, 1–7.
Anselmo, A.C., Mitragotri, S., 2014. An overview of clinical and commercial
impact of drug delivery systems. J. Control. Release 190, 15–28.
Araie, M., Takase, M., Sakai, Y., Ishii, Y., Yokoyama, Y., Kitagawa, M., 1982.
Beta-adrenergic blockers: ocular penetration and binding to the uveal
pigment. Jpn. J. Ophthalmol. 26, 248–63.
Azarian, S.M., McLeod, I., Lillo, C., Gibbs, D., Yates, J.R., Williams, D.S.,
2006.  Proteomic  analysis  of  mature  melanosomes  from  the  retinal
pigmented epithelium. J. Proteome Res. 5, 521–529.
Basu, P.K., Menon, I.A., Persad, S.D., Wiltshire, J.D., 1989. Binding of
chlorpromazine to cultured retinal pigment epithelial cells loaded with
melanin. Lens Eye Toxic. Res. 6, 229–240.
Báthory,  G.,  Szüts,  T.,  Magyar,  K.,  1987.  Studies  on  the  melanin  affinity  of
selegiline (deprenyl) and other amphetamine derivatives. Pol. J.
Pharmacol. Pharm. 39, 195–201.
Bhatnagar, V., Anjaiah, S., Puri, N., Darshanam, B.N., Ramaiah, A., 1993. pH
of  melanosomes  of  B  16  murine  melanoma  is  acidic:  its  physiological
importance  in  the  regulation  of  melanin  biosynthesis.  Arch.  Biochem.
Biophys. 307, 183–192.
Birch, D.G., Weleber, R.G., Duncan, J.L., Jaffe, G.J., Tao, W., 2013.
Randomized trial of ciliary neurotrophic factor delivered by encapsulated
cell intraocular implants for retinitis pigmentosa. Am. J. Ophthalmol. 156,
283–292.e1.
Bishop, P.N., 2000. Structural macromolecules and supramolecular
organisation of the vitreous gel. Prog. Retin. Eye Res. 19, 323–44.
Boulton,  M.,  1998.  Melanin  and  the  retinal  pigment  epithelium,  in:  The
Retinal Pigment Epithelium. pp. 68–84.
Bu, S.C., Kuijer, R., van der Worp, R.J., Li, X.R., Hooymans, J.M.M., Los, L.I.,
2015. The Ultrastructural Localization of Type II, IV, and VI Collagens at
the Vitreoretinal Interface. PLoS One 10, e0134325.
References
162
Bustamante, J., Bredeston, L., Malanga, G., Mordoh, J., 1993. Role of melanin
as a scavenger of active oxygen species. Pigment Cell Res. 6, 348–353.
Chan, J.E., Pridgen, T.A., Csaky, K.G., 2010. Episcleral clearance of sodium
fluorescein from a bioerodible sub-tenon’s  implant in the rat.  Exp.  Eye
Res. 90, 501–506.
Cheruvu, N.P.S., Amrite, A.C., Kompella, U.B., 2008. Effect of eye
pigmentation on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci.
49, 333–341.
Cheung, N., Mitchell, P., Wong, T.Y., 2010. Diabetic retinopathy. Lancet 376,
124–136.
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G.,
Pangalos, M.N., 2014. Lessons learned from the fate of AstraZeneca’s drug
pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–
431.
Crabb, J.W., Miyagi, M., Gu, X., Shadrach, K., West, K.A., Sakaguchi, H.,
Kamei, M., Hasan, A., Yan, L., Rayborn, M.E., Salomon, R.G., Hollyfield,
J.G., 2002. Drusen proteome analysis: an approach to the etiology of age-
related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 99, 14682–7.
Cunha-Vaz, J., 1979. The blood-ocular barriers. Surv. Ophthalmol. 23, 279–
96.
Cunha-Vaz, J., Bernardes, R., Lobo, C., 2011. Blood-retinal barrier. Eur. J.
Ophthalmol. 21, 3–9.
De Leo, D., Hickey, P.A., Meneghel, G., Cantor, C.H., 1999. Blindness, fear of
sight loss, and suicide. Psychosomatics 40, 339–344.
de Smet, M.D., Taylor, S.R.J., Bodaghi, B., Miserocchi, E., Murray, P.I., Pleyer,
U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., Lightman, S., 2011.
Understanding uveitis: The impact of research on visual outcomes. Prog.
Retin. Eye Res. 30, 452–470.
del Amo, E.M., Rimpelä, A.-K., Heikkinen, E., Kari, O.K., Ramsay, E., Lajunen,
T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., Subrizi,
A., Turunen, T., Reinisalo, M., Itkonen, J., Toropainen, E., Casteleijn, M.,
Kidron, H., Antopolsky, M., Vellonen, K.S., Ruponen, M., Urtti, A., 2017.
Pharmacokinetic aspects of retinal drug delivery. Prog. Retin. Eye Res. 57,
134–185.
del Amo, E.M., Urtti, A., 2015. Rabbit as an animal model for intravitreal
pharmacokinetics: Clinical predictability and quality of the published
data. Exp. Eye Res. 137, 111–124.
del Amo, E.M., Urtti, A., 2008. Current and future ophthalmic drug delivery
systems. A shift to the posterior segment. Drug Discov. Today 13, 135–
143.
del Amo, E.M., Vellonen, K.S., Kidron, H., Urtti, A., 2015. Intravitreal
clearance and volume of  distribution of  compounds in rabbits:  In silico
prediction and pharmacokinetic simulations for drug development. Eur.
J. Pharm. Biopharm. 95, 215–226.
Dias, M.F., Joo, K., Kemp, J.A., Fialho, S.L., da Silva Cunha, A., Woo, S.J.,
Kwon, Y.J., 2017. Molecular genetics and emerging therapies for retinitis
pigmentosa: Basic research and clinical perspectives. Prog. Retin. Eye
Res. (In press).
163
Ding, X., Patel, M., Chan, C.-C., 2009. Molecular pathology of age-related
macular degeneration. Prog. Retin. Eye Res. 28, 1–18.
Durairaj, C., 2016. Ocular pharmacokinetics, in: Whitcup, S., Azar, D. (Eds.),
Pharmacologic Therapy of Ocular Disease. Handbook of Experimental
Pharmacology.
Durand, M.L., 2017. Bacterial and Fungal Endophthalmitis. Clin. Microbiol.
Rev. 30, 597–613.
Eagle, R.C., 1988. Iris pigmentation and pigmented lesions: an ultrastructural
study. Trans. Am. Ophthalmol. Soc. 86, 581–687.
Eriksson, L., Jaworska, J., Worth, A.P., Cronin, M.T.D., McDowell, R.M.,
Gramatica, P., 2003. Methods for reliability and uncertainty assessment
and for applicability evaluations of classification- and regression-based
QSARs. Environ. Health Perspect. 111, 1361–75.
FDA,  2017.  Approved  Products  [WWW  Document].  URL
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyPro
ducts/ApprovedProducts/ucm589507.htm (accessed 2.13.18).
Feeney-Burns, L., Hilderbrand, E.S., Eldridge, S., 1984. Aging human RPE:
morphometric analysis of macular, equatorial, and peripheral cells.
Invest. Ophthalmol. Vis. Sci. 25, 195–200.
Fuller, B.B., Spaulding, D.T., Smith, D.R., 2001. Regulation of the catalytic
activity of preexisting tyrosinase in black and Caucasian human
melanocyte cell cultures. Exp. Cell Res. 262, 197–208.
Ghosh, J.G., Nguyen, A.A., Bigelow, C.E., Poor, S., Qiu, Y., Rangaswamy, N.,
Ornberg, R., Jackson, B., Mak, H., Ezell, T., Kenanova, V., De La Cruz, E.,
Carrion, A., Etemad-Gilbertson, B., Caro, R.G., Zhu, K., George, V., Bai,
J., Sharma-Nahar, R., Shen, S., Wang, Y., Subramanian, K.K.,
Fassbender, E., Maker, M., Hanks, S., Vrouvlianis, J., Leehy, B., Long, D.,
Prentiss, M., Kansara, V., Jaffee, B., Dryja, T.P., Roguska, M., 2017. Long-
acting protein drugs for the treatment of ocular diseases. Nat. Commun.
8, 1–10.
Gutiérrez-Hernández, J.-C., Caffey, S., Abdallah, W., Calvillo, P., González, R.,
Shih, J., Brennan, J., Zimmerman, J., Martínez-Camarillo, J.-C.,
Rodriguez, A.R., Varma, R., Santos, A., Sánchez, G., Humayun, M., 2014.
One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug
Delivery: A Pilot Study. Transl. Vis. Sci. Technol. 3, 8.
Halfter,  W.,  Dong,  S.,  Dong,  A.,  Eller,  A.W.,  Nischt,  R.,  2008.  Origin  and
turnover of ECM proteins from the inner limiting membrane and vitreous
body. Eye 22, 1207–1213.
Hämäläinen, K., Kananen, K., Auriola, S., Kontturi, K., Urtti, A., 1997.
Characterization of Paracellular and Aqueous Penetration Routes in
Cornea, Conjunctiva, and Sclera. Invest. Ophthalmol. Vis. Sci. 38, 627–
634.
Harrell, A.W., Sychterz, C., Ho, M.Y., Weber, A., Valko, K., Negash, K., 2015.
Interrogating the relationship between rat in vivo tissue distribution and
drug property data for >200 structurally unrelated molecules. Pharmacol.
Res. Perspect. 3, e00173.
Henrich, P.B., Monnier, C.A., Halfter, W., Haritoglou, C., Strauss, R.W., Lim,
R.Y.H., Loparic, M., 2012. Nanoscale Topographic and Biomechanical
Studies  of  the  Human  Internal  Limiting  Membrane.  Investig.
Opthalmology Vis. Sci. 53, 2561.
References
164
Herper, M., 2012. The Truly Staggering Cost Of Inventing New Drugs [WWW
Document]. Forbes. URL
https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-
staggering-cost-of-inventing-new-drugs/#5f4d6ca94a94 (accessed
1.29.18).
Hong,  L.,  Simon,  J.D.,  2007.  Current  understanding  of  the  binding  sites,
capacity, affinity, and biological significance of metals in melanin. J. Phys.
Chem. B 111, 7938–47.
Hornof, M., Toropainen, E., Urtti, A., 2005. Cell culture models of the ocular
barriers. Eur. J. Pharm. Biopharm. 60, 207–225.
Hu, D.-N., Simon, J.D., Sarna, T., 2008. Role of ocular melanin in ophthalmic
physiology and pathology. Photochem. Photobiol. 84, 639–644.
Hutton-Smith, L.A., Gaffney, E.A., Byrne, H.M., Maini, P.K., Gadkar, K.,
Mazer, N.A., 2017. Ocular Pharmacokinetics of Therapeutic Antibodies
Given by Intravitreal Injection: Estimation of Retinal Permeabilities
Using a 3-Compartment Semi-Mechanistic Model. Mol. Pharm. 14,
2690–2696.
Ings,  R.M.,  1984.  The  melanin  binding  of  drugs  and  its  implications.  Drug
Metab. Rev. 15, 1183–1212.
Ito, S., 1986. Reexamination of the structure of eumelanin. Biochim. Biophys.
Acta - Gen. Subj. 883, 155–161.
Ito, S., Pilat, A., Gerwat, W., Skumatz, C.M.B., Ito, M., Kiyono, A., Zadlo, A.,
Nakanishi, Y., Kolbe, L., Burke, J.M., Sarna, T., Wakamatsu, K., 2013.
Photoaging of human retinal pigment epithelium is accompanied by
oxidative modifications of its eumelanin. Pigment Cell Melanoma Res. 26,
357–366.
Ito,  S.,  Wakamatsu,  K.,  2008.  Chemistry  of  mixed  melanogenesis--pivotal
roles of dopaquinone. Photochem. Photobiol. 84, 582–592.
Jakubiak, P., Reutlinger, M., Mattei, P., Urtti, A., Alvarez-, Sanchez, R., 2017.
Use of melanin binding as drug targeting strategy to the back of the eye,
in: 30 Years of Drug Delivery Research Symposia. Kuopio, Finland.
Järvinen, K., Järvinen, T., Urtti, A., 1995. Ocular absorption following topical
delivery. Adv. Drug Deliv. Rev. 16, 3–19.
Johnson, T. V., Bull, N.D., Martin, K.R., 2011. Neurotrophic factor delivery as
a protective treatment for glaucoma. Exp. Eye Res. 93, 196–203.
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys,
J., Upreti, V., Zheng, M., Hall, S., 2015. Physiologically based
pharmacokinetic modeling in drug discovery and development: A
pharmaceutical industry perspective. Clin. Pharmacol. Ther. 97, 247–
262.
Kaliszan, R., Kaliszan, A., Wainer, I.W., 1993. Prediction of drug binding to
melanin using a melanin-based high-performance liquid
chromatographic stationary phase and chemometric analysis of the
chromatographic data. J. Chromatogr. 615, 281–8.
Karlsson, O., Lindquist, N.G., 2016. Melanin and neuromelanin binding of
drugs and chemicals: toxicological implications. Arch. Toxicol. 90, 1883–
1891.
165
Kidron, H., del Amo, E.M., Vellonen, K.-S., Urtti, A., 2012. Prediction of the
vitreal half-life of small molecular drug-like compounds. Pharm. Res. 29,
3302–3311.
Kidron, H., Vellonen, K.S., Del Amo, E.M., Tissari, A., Urtti, A., 2010.
Prediction  of  the  corneal  permeability  of  drug-like  compounds.  Pharm.
Res. 27, 1398–1407.
Kim, H., Robinson, M.R., Lizak, M.J., Tansey, G., Lutz, R.J., Yuan, P., Wang,
N.S., Csaky, K.G., 2004. Controlled Drug Release from an Ocular Implant:
An Evaluation Using Dynamic Three-Dimensional Magnetic Resonance
Imaging. Invest. Ophthalmol. Vis. Sci. 45, 2722.
Kim, S.H., Csaky, K.G., Wang, N.S., Lutz, R.J., 2008. Drug Elimination
Kinetics Following Subconjunctival Injection Using Dynamic Contrast-
Enhanced Magnetic Resonance Imaging. Pharm. Res. 25, 512–520.
Kinnunen, K., Petrovski, G., Moe, M.C., Berta, A., Kaarniranta, K., 2012.
Molecular mechanisms of retinal pigment epithelium damage and
development of age-related macular degeneration. Acta Ophthalmol. 90,
299–309.
Klaassen, I., Van Noorden, C.J.F., Schlingemann, R.O., 2013. Molecular basis
of the inner blood-retinal barrier and its breakdown in diabetic macular
edema and other pathological conditions. Prog. Retin. Eye Res. 34, 19–
48.
Klein, R., Lee, K.E., Knudtson, M.D., Gangnon, R.E., Klein, B.E.K., 2009.
Changes  in  visual  impairment  prevalence  by  period  of  diagnosis  of
diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy.
Ophthalmology 116, 1937–42.
Klosterman, L., Bettinger, C.J., 2016. Calcium-mediated control of
polydopamine film oxidation and iron chelation. Int. J. Mol. Sci. 18.
Koeberle, M.J., Hughes, P.M., Skellern, G.G., Wilson, C.G., 2003. Binding of
memantine to melanin: influence of type of melanin and characteristics.
Pharm. Res. 20, 1702–1709.
Krohne, T.U., Liu, Z., Holz, F.G., Meyer, C.H., 2012. Intraocular
pharmacokinetics of ranibizumab following a single intravitreal injection
in humans. Am. J. Ophthalmol. 154, 682–686.
Laitinen, A., Laatikainen, L., Härkänen, T., Koskinen, S., Reunanen, A.,
Aromaa, A., 2009. Prevalence of major eye diseases and causes of visual
impairment in the adult Finnish population: a nationwide population-
based survey. Acta Ophthalmol. 88, 463–471.
Larsson, B., Nilsson, M., Tjälve, H., 1981. The tissue-disposition of gentamicin
in rats. Acta pharmacol 48, 269–278.
Larsson, B.S., 1993. Interaction between chemicals and melanin. Pigment Cell
Res. 6, 127–133.
Le Goff, M.M., Bishop, P.N., 2008. Adult vitreous structure and postnatal
changes. Eye (Lond). 22, 1214–1222.
Leblanc, B., Jezequel, S., Davies, T., Hanton, G., Taradach, C., 1998. Binding
of drugs to eye melanin is not predictive of ocular toxicity. Regul. Toxicol.
Pharmacol. 28, 124–132.
Lee, V.H.L., Robinson, J.R., 1982. Disposition of pilocarpine in the pigmented
rabbit eye. Int. J. Pharm. 155–165.
References
166
Leeson, P.D., Springthorpe, B., 2007. The influence of drug-like concepts on
decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881–
890.
Lindquist, N.G., 1973. Chapter VII: Accumulation of adrenaline, dopamine,
noradrenaline and serotonin on melanin. Acta radiol. 14, 67–77.
Link, E.M., Brown, I., Carpenter, R.N., Mitchell, J.S., 1989. Uptake and
Therapeutic Effectiveness of 125I- and 211At-Methylene Blue for
Pigmented Melanoma in an Animal Model System. Cancer Res. 49, 4332–
4337.
Liu,  Y.,  Simon,  J.D.,  2003.  The  effect  of  preparation  procedures  on  the
morphology of melanin from the ink sac of Sepia officinalis. Pigment Cell
Res. 16, 72–80.
Lowrey,  a H., Famini, G.R., Loumbev, V., Wilson, L.Y., Tosk, J.M., 1997.
Modeling drug-melanin interaction with theoretical linear solvation
energy relationships. Pigment Cell Res. 10, 251–6.
Mateus, A., Gordon, L.J., Wayne, G.J., Almqvist, H., Axelsson, H., Seashore-
Ludlow, B., Treyer, A., Matsson, P., Lundbäck, T., West, A., Hann, M.M.,
Artursson, P., 2017a. Prediction of intracellular exposure bridges the gap
between target- and cell-based drug discovery. Proc. Natl. Acad. Sci. 114,
E6231–E6239.
Mateus, A., Matsson, P., Artursson, P., 2014. A high-throughput cell-based
method to predict the unbound drug fraction in the brain. J. Med. Chem.
57, 3005–3010.
Mateus, A., Matsson, P., Artursson, P., 2013. Rapid measurement of
intracellular unbound drug concentrations. Mol. Pharm. 10, 2467–2478.
Mateus, A., Treyer, A., Wegler, C., Karlgren, M., Matsson, P., Artursson, P.,
2017b. Intracellular drug bioavailability: a new predictor of system
dependent drug disposition. Sci. Rep. 7, 43047.
Maurice, D.M., Mishima, S., 1984. Ocular Pharmacology, in: Sears, M. (Ed.),
Handbook of Experimental Pharmacology. Springer-Verlag, Berlin-
Heidelberg, pp. 16–119.
Menon, I.A., Wakeham, D.C., Persad, S.D., Avaria, M., Trope, G.E., Basu, P.K.,
1992. Quantitative determination of the melanin contents in ocular
tissues from human blue and brown eyes. J. Ocul. Pharmacol. 8, 35–42.
Meredith,  P.,  Sarna,  T.,  2006.  The  physical  and  chemical  properties  of
eumelanin. Pigment Cell Res. 19, 572–94.
Morgan, P., Van Der Graaf, P.H., Arrowsmith, J., Feltner, D.E., Drummond,
K.S.,  Wegner,  C.D.,  Street,  S.D.A.,  2012.  Can  the  flow  of  medicines  be
improved? Fundamental pharmacokinetic and pharmacological
principles toward improving Phase II survival. Drug Discov. Today 17,
419–424.
Nadanaciva, S., Lu, S., Gebhard, D.F., Jessen, B.A., Pennie, W.D., Will, Y.,
2011. A high content screening assay for identifying lysosomotropic
compounds. Toxicol. Vitr. 25, 715–723.
Nafissi, N., Foldvari, M., 2016. Neuroprotective therapies in glaucoma: I.
Neurotrophic factor delivery. Wiley Interdiscip. Rev. Nanomedicine
Nanobiotechnology 8, 240–254.
167
Nagata, A., Mishima, H.K., Kiuchi, Y., Hirota, A., Kurokawa, T., Ishibashi, S.,
1993. Binding of antiglaucomatous drugs to synthetic melanin and their
hypotensive effects on pigmented and nonpigmented rabbit eyes. Jpn. J.
Ophthalmol. 37, 32–38.
Ono,  C.,  Tanaka,  M.,  2003.  Binding  characteristics  of  fluoroquinolones  to
synthetic levodopa melanin. J. Pharm. Pharmacol. 55, 1127–1133.
Ono, C., Yamada, M., Tanaka, M., 2003. Absorption, distribution and
excretion  of  14C-chloroquine  after  single  oral  administration  in  albino
and pigmented rats: binding characteristics of levofloxacin-related
radioactivity to melanin in vivo. J. Pharm. Pharmacol. 55, 1647–1654.
Park, S.J., Ahn, S., Woo, S.J., Park, K.H., H, H., A, F., 2015. Extent of
Exacerbation of Chronic Health Conditions by Visual Impairment in
Terms of Health-Related Quality of Life. JAMA Ophthalmol. 133, 1267.
Pearce, W., Hsu, J., Yeh, S., 2015. Advances in drug delivery to the posterior
segment. Curr. Opin. Ophthalmol. 26, 233–9.
Peeters, L., Sanders, N.N., Braeckmans, K., Boussery, K., Van de Voorde, J.,
De Smedt, S.C., Demeester, J., 2005. Vitreous: a barrier to nonviral ocular
gene therapy. Investig. Ophthalmol. Vis. Sci. 46, 3553–3561.
Pelkonen, L., Reinisalo, M., Morin-Picardat, E., Kidron, H., Urtti, A., 2016.
Isolation of Intact and Functional Melanosomes from the Retinal Pigment
Epithelium. PLoS One 11, e0160352.
Pelkonen, L., Sato, K., Reinisalo, M., Kidron, H., Tachikawa, M., Watanabe,
M., Uchida, Y., Urtti, A., Terasaki, T., 2017a. LC-MS/MS based
quantitation of ABC and SLC transporter proteins in plasma membranes
of  cultured  primary  human  retinal  pigment  epithelium  cells  and
immortalized ARPE19 cell line. Mol. Pharm. 14, 605–613.
Pelkonen, L., Tengvall-Unadike, U., Ruponen, M., Kidron, H., del Amo, E.M.,
Reinisalo,  M.,  Urtti,  A.,  2017b.  Melanin  binding  study  of  clinical  drugs
with cassette dosing and rapid equilibrium dialysis inserts. Eur. J. Pharm.
Sci. 109, 162–168.
Pescina, S., Santi, P., Ferrari, G., Padula, C., Cavallini, P., Govoni, P., Nicoli,
S., 2012. Ex vivo models to evaluate the role of ocular melanin in trans-
scleral drug delivery. Eur. J. Pharm. Sci. 46, 475–483.
Petternel, V., Krepler, K., Schauersberger, J., Wedrich, A., 2004. Fosfomycin
in human vitreous: –In–vitro investigation of the protein binding of
fosfomycin in human vitreous –Fosfomycin levels in the vitreous cavity
after intravenous administration. Investig. Ophthalmol. Vis. Sci. 45, 4930
ARVO Abstract.
Peynshaert, K., Devoldere, J., De Smedt, S.C., Remaut, K., 2017. In vitro and
ex vivo models to study drug delivery barriers in the posterior segment of
the eye. Adv. Drug Deliv. Rev. (In press).
Pezzella, A., D’Ischia, M., Napolitano, A., Palumbo, A., Prota, G., 1997. An
integrated approach to the structure of Sepia melanin. Evidence for a high
proportion of degraded 5,6-dihydroxyindole-2-carboxylic acid units in
the pigment backbone. Tetrahedron 53, 8281–8286.
Pfeifer, N.D., Harris, K.B., Yan, G.Z., Brouwer, K.L.R., 2013. Determination of
Intracellular Unbound Concentrations and Subcellular Localization of
Drugs  in  Rat  Sandwich-Cultured  Hepatocytes  Compared  with  Liver
Tissue. Drug Metab. Dispos. 41, 1949–1956.
References
168
Pitkänen, L., Pelkonen, J., Ruponen, M., Rönkkö, S., Urtti, A., 2004. Neural
retina limits the nonviral gene transfer to retinal pigment epithelium in
an in vitro bovine eye model. AAPS J. 6, e25.
Pitkänen, L., Ranta, V.-P., Moilanen, H., Urtti, A., 2007. Binding of betaxolol,
metoprolol and oligonucleotides to synthetic and bovine ocular melanin,
and prediction of drug binding to melanin in human choroid-retinal
pigment epithelium. Pharm. Res. 24, 2063–2070.
Pitkänen, L., Ranta, V.-P., Moilanen, H., Urtti, A., 2005. Permeability of
Retinal Pigment Epithelium: Effects of Permeant Molecular Weight and
Lipophilicity. Invest. Ophthalmol. Vis. Sci. 46, 641.
Potts,  A.M.,  1964.  The  reaction  of  uveal  pigment  in  vitro  with  polycyclic
compounds. Invest. Ophthalmol. 3, 405–416.
Potts,  A.M.,  1962.  The  concentration  of  phenothiazines  in  the  eye  of
experimental animals. Invest. Ophthalmol. 1, 522–30.
Prausnitz, M.R., Noonan, J.S., 1998. Permeability of cornea, sclera, and
conjunctiva: A literature analysis for drug delivery to the eye. J. Pharm.
Sci. 87, 1479–1488.
Prota,  G.,  1980.  Recent  advances  in  the  chemistry  of  melanogenesis  in
mammals. J. Invest. Dermatol. 75, 122–127.
Prota, G., Hu, D.N., Vincensi, M.R., McCormick, S.A., Napolitano, A., 1998.
Characterization  of  melanins  in  human  irides  and  cultured  uveal
melanocytes from eyes of different colors. Exp. Eye Res. 67, 293–299.
Radhika, M., Mithal, K., Bawdekar, A., Dave, V., Jindal, A., Relhan, N., Albini,
T., Pathengay, A., Flynn, H.W., 2014. Pharmacokinetics of intravitreal
antibiotics in endophthalmitis. J. Ophthalmic Inflamm. Infect. 4, 22.
Radwa?ska, A., Frackowiak, T., Ibrahim, H., Aubry, A.F., Kaliszan, R., 1995.
Chromatographic modelling of interactions between melanin and
phenothiazine and dibenzazepine drugs. Biomed. Chromatogr. 9, 233–
237.
Ramsay, E., Ruponen, M., Picardat, T., Tengvall, U., Tuomainen, M., Auriola,
S., Toropainen, E., Urtti, A., del Amo, E.M., 2017. Impact of Chemical
Structure on Conjunctival Drug Permeability: Adopting Porcine
Conjunctiva and Cassette Dosing for Construction of In Silico Model. J.
Pharm. Sci. 106, 2463–2471.
Ranta, V.-P., Mannermaa, E., Lummepuro, K., Subrizi, A., Laukkanen, A.,
Antopolsky, M., Murtomäki, L., Hornof, M., Urtti, A., 2010. Barrier
analysis of periocular drug delivery to the posterior segment. J. Control.
Release 148, 42–48.
Ranta, V.-P., Urtti, A., 2006. Transscleral drug delivery to the posterior eye:
prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 58, 1164–
1181.
Raposo, G., Marks, M.S., 2009. Melanosomes - dark organelles enlighten
endosomal membrane transport. Nat. Rev. Mol. Cell Biol. 8, 786–797.
Reilly, J., Williams, S.L., Forster, C.J., Kansara, V., End, P., Serrano-Wu, M.H.,
2015. High-Throughput Melanin-Binding Affinity and In Silico Methods
to Aid in the Prediction of Drug Exposure in Ocular Tissue. J. Pharm. Sci.
104, 3997–4001.
Remington, L.A., 2012. Clinical anatomy and physiology of the visual system,
3rd ed. Elsevier/Butterworth-Heinemann, S. Louis, Missouri.
169
Rimpelä, A.-K., Reinisalo, M., Hellinen, L., Grazhdankin, E., Kidron, H., Urtti,
A., del Amo, E.M., 2017. Implications of melanin binding in ocular drug
delivery. Adv. Drug Deliv. Rev. (In press).
Robbie, S.J., Leithner, P.L. Von, Ju, M., Lange, C.A., King, A.G., Adamson, P.,
Lee, D., Sychterz, C., Coffey, P., Ng, Y.S., Bainbridge, J.W., Shima, D.T.,
2013. Assessing a novel depot delivery strategy for noninvasive
administration of VEGF/PDGF RTK inhibitors for ocular neovascular
disease. Invest. Ophthalmol. Vis. Sci. 54, 1490–1500.
Robinson, M.R., Lee, S.S., Kim, H., Kim, S., Lutz, R.J., Galban, C., Bungay,
P.M., Yuan, P., Wang, N.S., Kim, J., Csaky, K.G., 2006. A rabbit model for
assessing the ocular barriers to the transscleral delivery of triamcinolone
acetonide. Exp. Eye Res. 82, 479–487.
Rosenthal, A., Kolb, H., Bergsma, D., Huxsoll, D., Hopkins, J., 1978.
Chloroquine retinopathy in the rhesus monkey. Invest. Ophthalmol. Vis.
Sci. 17, 1158–1175.
Rowland, M., Towzer, T.N., 2011. Clinical Pharmacokinetics and
Pharmacodynamics: Concepts and Applications, 4th ed. Lippincott
Williams & Wilkins, Baltimore, MD.
Rubio,  R.G.,  2014.  Retina  Today  -  Long-Acting  Anti-VEGF  Delivery
(July/August  2014)  [WWW  Document].  URL
http://retinatoday.com/2014/08/long-acting-anti-vegf-delivery
(accessed 1.18.18).
Salazar-Bookaman, M.M., Wainer, I., Patil, P.N., 1994. Relevance of drug-
melanin  interactions  to  ocular  pharmacology  and  toxicology.  J.  Ocul.
Pharmacol. 10, 217–39.
Salazar, M., Patil, P.N., 1976. An explanation for the long duration of mydriatic
effect of atropine in eye. Invest. Ophthalmol. 15, 671–673.
Salazar, M., Shimada, K., Patil, P.N., Pharmacology, O.F., 1976. Iris
pigmentation and atropine mydriasis. J. Pharmacol. Exp. Ther. 197, 79–
88.
Salminen,  L.,  Imre,  G.,  Huupponen,  R.,  1985.  The  effect  of  ocular
pigmentation on intraocular pressure responce to timolol. Acta
Ophthalmol. 63, 15–18.
Salminen, L., Urtti, A., 1984. Disposition of ophthalmic timolol in treated and
untreated rabbit eyes. A multiple and single dose study. Exp. Eye Res. 38,
203–206.
Salminen,  L.,  Urtti,  A.,  Periviita,  L.,  1984.  Effect  of  ocular  pigmentation  on
pilocarpine pharmacology in the rabbit eye. I. Drug distribution and
metabolism. Int. J. Pharm. 18, 17–24.
Sarin,  H.,  2010.  Physiologic  upper  limits  of  pore  size  of  different  blood
capillary  types  and  another  perspective  on  the  dual  pore  theory  of
microvascular permeability. J. Angiogenes. Res. 2, 14.
Sauer, M.J., Anderson, S.P., 1994. In vitro and in vivo studies of drug residue
accumulation in pigmented tissues. Analyst 119, 2553–2556.
Schauersberger, J., Jager, W., 2002. In-vitro investigation of the protein
binding of different antibiotics in the human vitreous. Investig.
Ophthalmol. Vis. Sci. 43, 1853–1853.
References
170
Schlingemann, R.O., Hofman, P., Klooster, J., Blaauwgeers, H.G.T., Van Der
Gaag, R., Vrensen, G.F.J.M., 1998. Ciliary muscle capillaries have blood-
tissue barrier characteristics. Exp. Eye Res. 66, 747–754.
Schmidt, S.Y., Peisch, R.D., 1986. Melanin concentration in normal human
retinal pigment epithelium. Regional variation and age-related reduction.
Invest. Ophthalmol. Vis. Sci. 27, 1063–1067.
Schwartz, K., Budenz, D., 2004. Current management of glaucoma. Curr.
Opin. Ophthalmol. 15, 119–26.
Sebag, J., 1987. Ageing of the vitreous. Eye 1, 254–262.
Sebag, J., Tang, M., Brown, S., Sadun, A.A., Charles, M.A., 1994. Effects of
Pentoxifylline on Choroidal Blood Flow in Nonproliferative Diabetic
Retinopathy. Angiology 45, 429–433.
Sliwoski, G., Kothiwale, S., Meiler, J., Lowe, E.W., Jr., 2014. Computational
methods in drug discovery. Pharmacol. Rev. 66, 334–95.
Sorkio, A., Hongisto, H., Kaarniranta, K., Uusitalo, H., Juuti-Uusitalo, K.,
Skottman, H., 2014. Structure and barrier properties of human embryonic
stem cell-derived retinal pigment epithelial cells are affected by
extracellular matrix protein coating. Tissue Eng. Part A 20, 622–634.
Spadea,  L.,  2014.  Treatment  of  Postoperative  Endophthalmitis.  US
Ophthalmic Rev. 7, 146.
Stefánsson, E., Bek, T., Porta, M., Larsen, N., Kristinsson, J.K., Agardh, E.,
2000. Screening and prevention of diabetic blindness. Acta Ophthalmol.
Scand. 78, 374–85.
Svensson, S.P., Lindgren, S., Powell, W., Green, H., 2003. Melanin inhibits
cytotoxic  effects  of  doxorubicin  and  daunorubicin  in  MOLT  4  cells.
Pigment Cell Res 16, 351–354.
Tanaka, M., Ono, C., Yamada, M., 2004. Absorption, distribution and
excretion of 14C-levofloxacin after single oral administration in albino
and pigmented rats: binding characteristics of levofloxacin-related
radioactivity to melanin in vivo. J.Pharm.Pharmacol. 56, 463–469.
Testorf, M.F., Kronstrand, R., Svensson, S.P.S., Lundstrom, I., Ahlner, J.,
2001. Characterization of [H-3]flunitrazepam binding to melanin. Anal.
Biochem. 298, 259–264.
Tetz, M., Rizzo, S., Augustin, A.J., 2012. Safety of submacular suprachoroidal
drug  administration  via  a  microcatheter:  retrospective  analysis  of
European treatment results. Ophthalmologica. 227, 183–9.
Tham, Y.-C., Li, X., Wong, T.Y., Quigley, H.A., Aung, T., Cheng, C.-Y., 2014.
Global  prevalence  of  glaucoma  and  projections  of  glaucoma  burden
through 2040: a systematic review and meta-analysis. Ophthalmology
121, 2081–90.
Theocharis, A.D., Papageorgakopoulou, N., Feretis, E., Theocharis, D.A.,
2002. Occurrence and structural characterization of versican-like
proteoglycan in human vitreous. Biochimie 84, 1237–43.
Tratta, E., Pescina, S., Padula, C., Santi, P., Nicoli, S., 2014. In vitro
permeability  of  a  model  protein  across  ocular  tissues  and  effect  of
iontophoresis on the transscleral delivery. Eur. J. Pharm. Biopharm. 88,
116–22.
171
Tsuchiya, M., Hayasaka, S., Mizuno, K., 1987. Affinity of ocular acid-insoluble
melanin for drugs in vitro. Invest. Ophthalmol. Vis. Sci. 28, 822–825.
Tsukamoto, K., Palumbo, A., D’Ischia, M., Hearing, V.J., Prota, G., 1992. 5,6-
Dihydroxyindole-2-carboxylic acid is incorporated in mammalian
melanin. Biochem. J. 491–5.
Tuuminen, R., Uusitalo-Järvinen, H., Aaltonen, V., Hautala, N., Kaipiainen,
S., Laitamäki, N., Ollila, M., Rantanen, J., Välimäki, S., Sipilä, R.,
Laukkala, T., Komulainen, J., Tommila, P., Immonen, I., Tuulonen, A.,
Kaarniranta, K., 2017. The Finnish national guideline for diagnosis,
treatment and follow-up of patients with wet age-related macular
degeneration. Acta Ophthalmol. 95, 1–9.
Ulrich, J.N., Spannagl, M., Kampik, A., Gandorfer, A., 2008. Components of
the fibrinolytic system in the vitreous body in patients with vitreoretinal
disorders. Clin. Experiment. Ophthalmol. 36, 431–436.
Urtti, A., 2006. Challenges and obstacles of ocular pharmacokinetics and drug
delivery. Adv. Drug Deliv. Rev. 58, 1131–1135.
Urtti, A., Salminen, L., Kujari, H., Jäntti, V., 1984. Effect of ocular
pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug
response. Int J Pharm Sci 19, 53–61.
Vellonen, K.-S., Hellinen, L., Mannermaa, E., Ruponen, M., Urtti, A., Kidron,
H.,  2017.  Expression,  activity  and  pharmacokinetic  impact  of  ocular
transporters. Adv. Drug Deliv. Rev. (In press).
Vellonen, K.-S., Soini, E.-M., del Amo, E.M., Urtti, A., 2016. Prediction of
ocular drug distribution from systemic blood circulation. Mol. Pharm. 13,
2906–2911.
Vuleti?,  G., Sarlija, T., Benjak, T., 2016. Quality of life in blind and partially
sighted people. J. Appl. Heal. Sci. 2, 101–112.
Wakamatsu, K., Hu, D.-N., McCormick, S.A., Ito, S., 2008. Characterization of
melanin  in  human  iridal  and  choroidal  melanocytes  from  eyes  with
various colored irides. Pigment Cell Melanoma Res. 21, 97–105.
Ward, W.C., Simon, J.D., 2007. The differing embryonic origins of retinal and
uveal (iris/ciliary body and choroid) melanosomes are mirrored by their
phospholipid composition. Pigment Cell Res. 20, 61–69.
Watt, A.A.R., Bothma, J.P., Meredith, P., Nighswander-Rempel, S., Pederson,
M.R., Moore, E., Pederson, M.R., Simon, J.D., 2009. The supramolecular
structure of melanin. Soft Matter 5, 3754.
Watts, K.P., Fairchild, R.G., Slatkin, D.N., Greenberg, D., Packer, S., Atkins,
H.L., Hannon, S.J., 1981. Melanin Content of Hamster Tissues, Human
Tissues, and Various Melanomas. Cancer Res. 41, 467–472.
Weiter, J.J., Delori, F.C., Wing, G.L., Fitch, K.A., 1986. Retinal pigment
epithelial lipofuscin and melanin and choroidal melanin in human eyes.
Invest. Ophthalmol. Vis. Sci. 27, 145–152.
Williams, G.A., 2014. IVT Injections: Health Policy Implications. Rev.
Ophthalmol.
Wong, W.L., Su, X., Li, X., Cheung, C.M.G., Klein, R., Cheng, C.Y., Wong, T.Y.,
2014. Global prevalence of age-related macular degeneration and disease
burden  projection  for  2020  and  2040:  A  systematic  review  and  meta-
analysis. Lancet Glob. Heal. 2, e106–e116.
References
172
Wrze?niok, D., Beberok, A., Otr?ba, M., Buszman, E., 2013. Effect of
streptomycin on melanogenesis and antioxidant status in melanocytes.
Mol. Cell. Biochem. 383, 77–84.
Xu, Q., Boylan, N.J., Suk, J.S., Wang, Y.-Y., Nance, E.A., Yang, J.-C.,
McDonnell, P.J., Cone, R.A., Duh, E.J., Hanes, J., 2013. Nanoparticle
diffusion in, and microrheology of, the bovine vitreous ex vivo. J. Control.
Release 167, 76–84.
Zajac, G.W., Gallas, J.M., Cheng, J., Eisner, M., Moss, S.C., Alvarado-
Swaisgood,  A.E.,  1994.  The  fundamental  unit  of  synthetic  melanin:  a
verification by tunneling microscopy of X-ray scattering results. Biochim.
Biophys. Acta - Gen. Subj. 1199, 271–278.
Zane, P.A., Brindle, S.D., Gause, D.O., O’Buck, A.J., Raghavan, P.R., Tripp,
S.L., 1990. Physicochemical factors associated with binding and retention
of  compounds  in  ocular  melanin  of  rats:  correlations  using  data  from
whole-body autoradiography and molecular modeling for multiple linear
regression analyses. Pharm. Res. 7, 935–941.
Zhu, Q., Ziemssen, F., Henke-Fahle, S., Tatar, O., Szurman, P., Aisenbrey, S.,
Schneiderhan-Marra, N., Xu, X., Grisanti, S., Grisanti, S., 2008. Vitreous
Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in
Patients with Choroidal Neovascularization. Ophthalmology 115, 1750–
1755.e1.
Ocular Pharmacokinetic Effects of Drug Binding 
to Melanin Pigment and the Vitreous Humor
ANNA-KAISA RIMPELÄ
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis 36/2018
36/2018
Helsinki 2018                       ISSN 2342-3161                 ISBN 978-951-51-4317-4  
A
N
N
A
-K
A
ISA
 R
IM
P
E
LÄ
   O
cular P
harm
acokin
etic E
ffects of D
rug B
in
din
g to M
elan
in
 P
igm
en
t an
d the V
itreous H
um
or
Recent Publications in this Series
17/2018 Richa Gupta
Association and Interplay of Genetic and Epigenetic Variants in Smoking Behavior
18/2018 Patrick Vingadas Almeida
Multifunctional Porous Silicon Based Nanocomposites for Cancer Targeting and Drug Delivery
19/2018 Lena Sjöberg
Reproductive Health in Women with Childhood-onset Type 1 Diabetes in Finland
20/2018 Perttu Päiviö Salo
Studies on the Genetics of Heart Failure
21/2018 Andrew Erickson
In Search of Improved Outcome Prediction of Prostate Cancer – A Biological and Clinical 
Approach
22/2018 Imrul Faisal
Genetic Regulation of Mammalian Spermatogenesis - Studies of USF1 and MAD2
23/2018 Katja Wikström
Socioeconomic Differences in the Development and Prevention of Type 2 Diabetes: Focus on 
Education and Lifestyle
24/2018 Laura Ollila
Genotype-Phenotype Correlations in Dilated Cardiomyopathy
25/2018 Elina Engberg
Physical Activity, Pregnancy and Mental Well-Being: Focusing on Women at Risk for Gestational 
Diabetes
26/2018 Anni Niskakoski
Molecular Alterations of Endometrial and Ovarian Tumorigenesis in Lynch  Syndrome Mutation 
Carriers and the General Population
27/2018 Katariina Maaninka
Atheroinflammatory Properties of LDL and HDL Particles Modified by Human Mast Cell 
Neutral Proteases
28/2018 Sonja Paetau
Neuronal ICAM-5 Regulates Synaptic Maturation and Microglia Functions
29/2018 Niina Kaartinen
Carbohydrates in the Diet of Finnish Adults - Focus on Intake Assessment and Associations with 
Other Dietary Components and Obesity
30/2018 Tuija Jääskeläinen
Public Health Importance of Vitamin D: Results from the Population-based Health 2000/2011 
Survey
31/2018 Tiina Lipiäinen
Stability and Analysis of Solid-State Forms in Pharmaceutical Powders
32/2018 Johanna Ruohoalho
Complications and Their Registration in Otorhinolaryngology – Head and Neck Surgery:  
Special emphasis in Tonsil Surgery Quality Registration
33/2018 Alok Jaiswal
Integrative Bioinformatics of Functional and Genomic Profiles for Cancer Systems Medicine
34/2018 Riikka Uotila
Let’s Get Cracking —Nut Allergy Diagnostics and Peanut Oral Immunotherapy
35/2018 Solomon Olusegun Nwhator
Association between a-MMP-8 Chairside Test for Chronic Periodontitis and Selected 
Reproductive Health Parameters
DRUG RESEARCH PROGRAM
DIVISION OF PHARMACEUTICAL BIOSCIENCES
FACULTY OF PHARMACY
DOCTORAL PROGRAMME IN DRUG RESEARCH 
UNIVERSITY OF HELSINKI
